WO2019027808A1 - Appareil de commande et procédés associés pour l'administration d'un traitement de plaie - Google Patents

Appareil de commande et procédés associés pour l'administration d'un traitement de plaie Download PDF

Info

Publication number
WO2019027808A1
WO2019027808A1 PCT/US2018/043957 US2018043957W WO2019027808A1 WO 2019027808 A1 WO2019027808 A1 WO 2019027808A1 US 2018043957 W US2018043957 W US 2018043957W WO 2019027808 A1 WO2019027808 A1 WO 2019027808A1
Authority
WO
WIPO (PCT)
Prior art keywords
pressure
enclosed space
wound
fluid
input
Prior art date
Application number
PCT/US2018/043957
Other languages
English (en)
Inventor
Edward D. Lin
Original Assignee
Lin Edward D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/663,713 external-priority patent/US10729826B2/en
Priority claimed from US15/663,710 external-priority patent/US10780201B2/en
Priority claimed from US15/663,709 external-priority patent/US20190030226A1/en
Priority claimed from US15/663,714 external-priority patent/US11712373B2/en
Priority claimed from US15/663,708 external-priority patent/US11559622B2/en
Application filed by Lin Edward D filed Critical Lin Edward D
Priority to CN201880049910.5A priority Critical patent/CN110944608B/zh
Publication of WO2019027808A1 publication Critical patent/WO2019027808A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00051—Accessories for dressings
    • A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0203—Adhesive bandages or dressings with fluid retention members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/71—Suction drainage systems
    • A61M1/74—Suction control
    • A61M1/75—Intermittent or pulsating suction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/71—Suction drainage systems
    • A61M1/77—Suction-irrigation systems
    • A61M1/772—Suction-irrigation systems operating alternately
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/80—Suction pumps
    • A61M1/82—Membrane pumps, e.g. bulbs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/84—Drainage tubes; Aspiration tips
    • A61M1/85—Drainage tubes; Aspiration tips with gas or fluid supply means, e.g. for supplying rinsing fluids or anticoagulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/91—Suction aspects of the dressing
    • A61M1/915—Constructional details of the pressure distribution manifold
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/91—Suction aspects of the dressing
    • A61M1/918—Suction aspects of the dressing for multiple suction locations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/92—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with liquid supply means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/94—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with gas supply means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/96—Suction control thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00646—Medication patches, e.g. transcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/30—Gas therapy for therapeutic treatment of the skin

Definitions

  • the present disclosure relates to medical devices, and, more particularly, to apparatus and related methods for delivering therapy to wound beds.
  • a wound bed includes a localized region of tissue that has lost skin and been affected by hostile factors, resulting in, for example, cellular abnormalities such as swelling, inflammation, degradation, infection, or cell death.
  • the wound bed may include varying degrees of exposure of underlying layers and structures, along with possible infections and tissue changes.
  • the wound bed represents an unhealed wound.
  • a healed wound is a skin surface that was previously injured but the focal breach is now entirely sealed and covered by varying amounts of epidermis and scar tissue.
  • the wound bed may lie within a wound boundary that extends around the affected region on the skin surface of the skin.
  • the wound bed may extend contiguously in depth within the dermis, and the wound bed may extend subcutaneously, for example, into fat, muscle, or beyond.
  • the wound bed may include undermined flaps, sinuses, tunnels, and fistulae and the surrounding affected tissues.
  • An example of a wound bed including some reference anatomy is illustrated in Figure 1.
  • Wound boundary refers to the boundary of the wound bed at a skin surface of the skin.
  • NPWT negative pressure wound therapy
  • the wound bed is packed with the dressing and the evacuation tube is placed about the dressing.
  • the cover is then placed over the wound bed and attached adhesively to the skin surface around the wound bed to seal the wound bed, dressing, and evacuation tube in place.
  • air within the region between the sheet and the wound bed is evacuated through the evacuation tube, which is in fluid communication with the dressing, to produce a suction pressure p s within an enclosed space between the cover and the wound bed that is less than the ambient pressure p am b.
  • the wound bed and surrounding skin are as the suction pressure p s . is decreased below the ambient pressure p am b. Exudate from the wound bed may be transmitted through the dressing and then evacuated through the evacuation tube. The wound may be subjected to a suction pressure p s that is static and typically between around -80 mm Hg to around -175 mm Hg below ambient pressure pamb.
  • the suction pressure p s may be maintained statically continually for weeks, if not months, until end of therapy, except during dressing changes. Because capillaries are exceedingly thin-walled microscopic tubules, capillaries are easily collapsed shut by the suction pressure. Studies have shown that while blood flow increases in proportion to suction pressure p s at a further distance of 2.5 cm from the wound edge, blood flow is diminished detrimentally by at least as much closer to the wound bed, at 0.5 cm from the wound edge, where increased blood flow is most needed.
  • the evacuation tube may become clogged by the proteinaceous exudate, which may result in interruption of the NPWT.
  • the suction pressure p s may be inaccurately sensed, falsely indicating that suction pressure p s is at the desired level when in fact, due to exudate plug, there is little or no suction pressure within the enclosed space over the wound bed. Because the dressing is tedious to apply and painful to remove, as a practical matter, it is deemed not feasible to take it off repeatedly in order to attach other devices to deliver other therapies.
  • NPWT has been combined with instillation of an antibiotic solution in order to treat extra difficult wound beds.
  • This system interposes one or more episodes of liquid therapy a few times a day in which the solution is introduced to the wound bed and allowed to "dwell” for a period of time and then removed.
  • This "NPWT with instillation” requires a premeasurement of the volume of the wound bed, entering that volume into the infusion pump so that no excessive amount of instillation takes place that could jeopardize the integrity of the seal of the cover around the wound. Extra time, equipment and skilled attention is required to administer NPWT combined with instillation.
  • HBO total body hyperbaric oxygen
  • the patient is placed in a hyperbaric chamber and exposed, typically, to 2.5 ATA (atmospheres Absolute) of medically pure oxygen for 90 minutes. Exposure past 120 minutes increases the risk of oxygen toxicity, probably due to the increased formation of superoxide, H2O2 or other oxidizing free radicals. Seizures and other serious consequences may result.
  • ATA atmospheres Absolute
  • Such a 90-minute session avails oxygen enrichment to the wound bed for a mere 6% of a day.
  • the Medicare branch of the US Government usually approves HBO treatment for 30-40 sessions at a time at a cost per session of many hundreds to $1,000.
  • the wound therapy apparatus disclosed herein includes a wound interface that defines an enclosed space over a wound bed that is fluid tight when secured to a skin surface around the wound bed.
  • the wound therapy apparatus includes a control group that cooperates with the wound interface to regulate input of input fluid comprising a gas having an O2 concentration greater than atmospheric air into the enclosed space and to regulate the withdrawal of output fluid from the enclosed space in order to vary an actual pressure p a within the enclosed space generally between a minimum pressure p mm and a maximum pressure the minimum pressure pmm being less than ambient pressure p am b, in various aspects.
  • the input of the gas having an O2 concentration greater than atmospheric air is sequential with withdrawal of the gas having an O2 concentration greater than atmospheric air, in various aspects.
  • the wound therapy apparatus disclosed herein includes a liquid source of liquid, a gas source of gas having an O2 concentration greater than that of atmospheric air, and a wound interface engaged with a skin surface around a wound bed to define an enclosed space about the wound bed, the enclosed space being fluid tight.
  • the wound therapy apparatus includes a control group in operable communication with the liquid source, the gas source, and the enclosed space to selectively input liquid and gas into the enclosed space and to regulate the withdrawal of output fluid from the enclosed space, in various aspects.
  • Related methods of use of the wound therapy apparatus disclosed herein may include the step of engaging a wound interface with a skin surface around a wound bed thereby defining an enclosed space, and the step of regulating the input of input fluid into the enclosed space in sequence with regulating the withdrawal of output fluid from the enclosed space using a control group thereby altering periodically the actual pressure p a within the enclosed space according to a pressure cycle of a target pressure po, in various aspects.
  • the pressure cycle has a minimum pressure p mm and a maximum pressure p ma x, and the input fluid comprises a gas having an O2 concentration greater than atmospheric air, in various aspects.
  • Figure 1 by cross-sectional view an exemplary wound bed that demonstrates undermining, wound tunneling, and fistulae;
  • Figure 2 illustrates by schematic diagram an exemplary implementation of a wound therapy apparatus
  • Figure 3A illustrates by schematic diagram a second exemplary implementation of a wound therapy apparatus in a first operational configuration
  • Figure 3B illustrates by schematic diagram the exemplary implementation of a wound therapy apparatus of Figure 3 A in a second operational configuration
  • Figure 4A illustrates by cut-away schematic diagram a portion of the exemplary wound therapy apparatus of Figure 3 A in the first operational configuration
  • Figure 4B illustrates by cut-away schematic diagram a portion of the exemplary wound therapy apparatus of Figure 3 A in the second operational configuration
  • Figure 5 by schematic diagram operational states of the exemplary wound therapy apparatus of Figure 3 A;
  • Figure 6A illustrates by cut-away elevation view a third exemplary implementation of a wound therapy apparatus at a first stage of operation
  • Figure 6B illustrates by cut-away elevation view portions of the exemplary wound interface of Figure 6A at a second stage of operation
  • Figure 7 illustrates by cut-away perspective view a fourth exemplary implementation of a wound interface
  • Figure 8 illustrates by cut-away elevation view a fifth exemplary implementation of a wound interface
  • Figure 9A illustrates by Cartesian plot an exemplary pressure cycle as may be delivered to a wound bed by the wound therapy apparatus, such as the exemplary wound therapy apparatus of Figures 2, 3 A, 6 A, 7, and 8;
  • Figure 9B illustrates by Cartesian plot a second exemplary pressure cycle as may be delivered to a wound bed by the wound therapy apparatus, such as the exemplary wound therapy apparatus of Figures 2, 3 A, 6 A, 7, and 8;
  • Figure 9C illustrates by Cartesian plot a third exemplary pressure cycle as may be delivered to a wound bed by the wound therapy apparatus, such as the exemplary wound therapy apparatus of Figures 2, 3 A, 6A, 7, and 8;
  • Figure 9D illustrates by Cartesian plot a fourth exemplary pressure cycle as may be delivered to a wound bed by the wound therapy apparatus, such as the exemplary wound therapy apparatus of Figures 2, 3A, 6A, 7, and 8;
  • Figure 9E illustrates by Cartesian plot a fifth exemplary pressure cycle as may be delivered to a wound bed by the wound therapy apparatus, such as the exemplary wound therapy apparatus of Figures 2, 3A, 6A, 7, and 8;
  • Figure 9F illustrates by Cartesian plot a sixth exemplary pressure cycle as may be delivered to a wound bed by the wound therapy apparatus, such as the exemplary wound therapy apparatus of Figures 2, 3A, 6A, 7, and 8;
  • Figure 9G illustrates by Cartesian plot a seventh exemplary pressure cycle as may be delivered to a wound bed by the wound therapy apparatus, such as the exemplary wound therapy apparatus of Figures 2, 3A, 6A, 7, and 8;
  • Figure 9H illustrates by Cartesian plot an eighth exemplary pressure cycle as may be delivered to a wound bed by the wound therapy apparatus, such as the exemplary wound therapy apparatus of Figures 2, 3A, 6A, 7, and 8;
  • Figure 91 illustrates by Cartesian plot a ninth exemplary pressure cycle as may be delivered to a wound bed by the wound therapy apparatus, such as the exemplary wound therapy apparatus of Figures 2, 3A, 6A, 7, and 8;
  • Figure 9J illustrates by Cartesian plot a tenth exemplary pressure cycle as may be delivered to a wound bed by the wound therapy apparatus, such as the exemplary wound therapy apparatus of Figures 2, 3A, 6A, 7, and 8; and
  • Figure 10 illustrates by process flow chart an exemplary method of use of the wound therapy apparatus such as the exemplary wound therapy apparatus of Figures 2, 3A, 6A, 7, and
  • the wound therapy apparatus includes a wound interface engaged with a skin surface around a wound bed to define an enclosed space over the wound bed, the enclosed space being fluid tight.
  • a control group cooperates with the wound interface to regulate input of input fluid into the enclosed space and to regulate the withdrawal of output fluid from the enclosed space in order to vary an actual pressure pa within the enclosed space generally between a minimum pressure p mm and a maximum pressure p ma x, in various aspects.
  • the minimum pressure p mm is less than ambient pressure p am b, and the input of the gas is sequential with withdrawal of the gas having an O2 concentration greater than atmospheric air, in various aspects.
  • the control group may vary periodically the actual pressure p a within the enclosed space in a pressure cycle between the minimum pressure p mm and the maximum pressure p ma x.
  • the gas may have an O2 concentration greater than atmospheric air (about 20.95% by volume or about 0.2095 mole O2 per mole of dry air),
  • Fluid includes, liquid(s), gas(ses), and combinations thereof.
  • Liquid includes, for example, saline solution, Dakin's solution, proteolytic enzyme solution, biofilm degradation solution, cytokines, antibiotic lavage, amniotic fluid, platelet-enriched plasma, antibiotic, analgesic, anesthetic, and combinations thereof.
  • Liquid may include saline or water based solutions that, for example, irrigate the wound bed, remove bio-burden, or moisturize the wound bed.
  • Gas may include, for example, air, oxygen, nitric oxide, nitrogen, or suitable therapeutic or inert gasses, and combinations thereof.
  • Gas for example, may be nitric oxide diluted in nitrogen at about 200 ppm to about 800 ppm.
  • Gas input into the enclosed space to increase the actual pr6SSUr6 pa within the enclosed space from the minimum pressure pmm to the maximum pressure pmax may have an O2 concentration greater than atmospheric air (about 21.95% by volume), in various aspects.
  • the gas may be medical grade oxygen. Medical grade oxygen may conform to certain standards, for example, United States Food and Drug Administration standards or other appropriate regulatory standards. In various aspects, the medical grade oxygen may be United States Pharmacopoeia grade oxygen.
  • input fluid 16 supplied to wound interface 115 may be a liquid that may have some therapeutic benefit.
  • Sequential withdrawal of output fluid from the enclosed space and input of input fluid into the enclosed space means that withdrawal of output fluid and the input of input fluid does not occur simultaneously.
  • Input fluid may be being input into the enclosed space or output fluid may be being withdrawn from the enclosed space but not the input of input fluid simultaneously with output of output fluid.
  • An exception may be when the input fluid is a liquid and the liquid is input and withdrawn simultaneously, for example, during irrigation of the wound bed.
  • Simultaneous input of liquid may irrigate or flush the wound bed with an amount of liquid several times the volume of the enclosed space to cleanse the wound bed of, for example, microbes, cellular debris, and biofilm.
  • p max may be around ambient pressure p am b or greater.
  • Using fluid with O2 concentration greater than atmospheric air results in 2 minutes of topical oxygen therapy around ambient or higher pressure in this example.
  • Ten 2-minute cycles of such topical oxygen therapy per hour add up to 240 cycles daily that equals 8 hours per day of topical oxygen therapy without decreasing the amount of negative pressure therapy delivered. This may deliver additional therapy without displacing or shortening the fundamental underlying pressure therapy.
  • p m m, pmax andpamb are approximate and relative, and may vary from cycle to cycle depending on apparatus and environmental factors including altitude. The therapeutic results are substantially achieved regardless whether the target pressures are attained exactly or approximated.
  • the pressure cycle has a 6-minute duration with pressure po at pmin for 3 minutes and the pressure relieved to p ma x for 3 minutes (1/2 of the duration of the pressure cycle), which results in delivery of topical oxygen therapy to the wound bed around ambient pressure or higher totaling 12 hours per day. Therefore, towards the latter healing phase when edema and exudation is greatly diminished such that negative pressure p mm is needed less, the duration of topical oxygen can be correspondingly increased to accelerate the next phase of healing.
  • every nth pressure cycle (where n is any suitable number such as 2 through 60 or even 120 or more) is relieved with a liquid.
  • the methods of wound therapy include, in various aspects, providing a therapy regimen to the wound bed within an enclosed space, the therapy regimen comprising delivering consecutively a number of pressure cycles of an actual pressure p a within the enclosed space, each pressure cycle generally comprising a pressure range p mm ⁇ p a ⁇ p ma x where p mm ⁇ p am b and pamb ⁇ pmax with p m in ⁇ p m ax and pamb is the ambient pressure, an input fluid comprising gas(es) and liquids being introduced into the enclosed space as each pressure cycle progresses from pmm to pmax. Pressures p m m, pmax, and the duration of the pressure cycle as well as the fluid(s) introduced into the enclosed space may vary from pressure cycle to pressure cycle depending on the desired therapeutic goal desired.
  • the methods of wound therapy may include the step of engaging a wound interface with a skin surface around a wound bed thereby defining an enclosed space.
  • the methods of wound therapy may include the step of regulating the input of input fluid into the enclosed space in sequence with regulating the withdrawal of output fluid from the enclosed space using a control group thereby altering periodically the actual pressure p a within the enclosed space generally according to a pressure cycle of a target pressure po, the pressure cycle having a minimum pressure p m m and a maximum pressure p ma x, the input fluid comprising a gas having an O2 concentration greater than atmospheric air.
  • the methods of wound therapy may include the step of removing exudate from the enclosed space by flowing the output fluid to a reservoir.
  • the input fluid may be a liquid in which case the input of the input liquid and the output of the output liquid may occur sequentially or simultaneously depending the therapeutic goal.
  • the methods of wound therapy may include the step of receiving data from a user with an I/O interface; and communicating the data from the user I/O to a controller thereby altering targeted aspects of the pressure cycle.
  • the methods of wound therapy may include the step of delivering a therapy regimen to the wound bed, the therapy regimen comprising a series of pressure cycles of the actual pressure pa wuhm the enclosed space.
  • the resulting O2 enrichment may resuscitate the hypoxic wound cells, may sustain the revived cells in cell division and collagen synthesis, may inhibit the growth of anaerobic bacteria, may enhance the efficacy of antibiotics, and may enhance survival of stem cells and tissue grafts, and augment the therapeutic benefits of other bioengineered materials .
  • O2 enrichment provided to the wound bed may be beneficial because the O2 enrichment is [1] under a favorable concentration gradient, [2] at a favorable pressure gradient that does not impede baseline arterial perfusion (such as between 20-60 mm Hg, but may be higher for brief durations), and [3] during a period of relative reflex hyperemia in regions of tissue where capillaries may have previously been collapsed under suction.
  • baseline arterial perfusion such as between 20-60 mm Hg, but may be higher for brief durations
  • the amplitude and period of the O2 delivery may additionally serve and be programmed to provide a form of external pulsation of pressurized O2, with beneficial circulatory effect akin in some respects to providing external CPR to the wound bed.
  • the methods of wound therapy may include the step of inputting liquid into the enclosed space and may include the step of withdrawing liquid from the enclosed space.
  • the methods of wound therapy may include lavage of the wound bed using liquid input into the enclosed space and withdrawn from the enclosed space in sequence.
  • the method of wound therapy may include providing a therapy to the wound bed by inputting liquid having therapeutic properties into the enclosed space.
  • the therapeutic properties may include, for example, proteolytic, analgesic, antimicrobial, or healing properties.
  • the liquid input and output with respect to the enclosed space may occur simultaneously instead of sequentially.
  • Ambient pressure p am b refers to the pressure in a region surrounding the wound therapy apparatus.
  • Ambient pressure p am b may refer to atmospheric pressure, hull pressure within an aircraft where the wound therapy apparatus is being utilized, or pressure maintained generally within a building or other structure where the wound therapy apparatus is being utilized.
  • Ambient pressure p am b may vary, for example, with elevation or weather conditions.
  • Pressure p mm refers to the minimum pressure achieved within the enclosed space of the wound therapy apparatus, and periodically varying of pressure po, pressure variation, varying pressure, and similar term refer to changes of pressure po within the enclosed space over time, in various aspects.
  • Pressure p ma x refers to the maximum pressure achieved within the enclosed space of the wound therapy apparatus.
  • Exudate includes, for example, proteinaceous liquids exuded from the wound bed, along with various plasma and blood components and other bodily fluids. Exudate may additionally include waste liquids such as irrigation liquid.
  • fluid-tight or related terms means sufficiently leak -resistant to allow insufflation or vacuum suction to create actual pressure pa within the enclosed space of a wound interface that may be above or below ambient pressure p am b, or to substantially retain fluids including both gasses and liquids within the enclosed space other than by passage through one or more lumen that may fluidly communicate with the enclosed space, in some aspects.
  • fluid-tight or related terms means sufficiently leak-resistant to allow insufflation or vacuum suction to maintain actual pressure pa within the enclosed space of a wound interface t above or below ambient pressure p am b, in various aspects.
  • distal and proximal are defined from the point of view of a user, such as a physician, nurse, or medical technician, treating a patient with a wound therapy apparatus.
  • a distal portion of the wound therapy apparatus is oriented toward the patient while a proximal portion of the wound therapy apparatus is oriented toward the healthcare provider.
  • a distal portion of a structure may be closest to the patient while a proximal portion of the structure may be closest to the user treating the patient.
  • a wound interface that is deformation resistant resists collapse and substantially maintains its shape, including defining an enclosed space within sufficient to draw a portion of wound bed towards or into the enclosed space, including the wound bed occupying the enclosed space, when subjected to actual pressure p a ⁇ p am b, in various aspects.
  • at least portions of the wound interface that defines the enclosed space may be essentially rigid.
  • the wound interface in various aspects, is sufficiently deformation resistant to remain sealingly secured to skin surface and fluid-tight over pressure range p mm ⁇ p a ⁇
  • Apparatus, related methods of use, and related compositions of matter disclosed herein may be implemented, at least in part, in software having the form of computer readable instructions operably received by one or more computers to cause, at least in part, the one or more computers to function as the apparatus or to implement the steps of the methods of use.
  • the methods of use disclosed herein may be implemented as a combination of hardware and operatively received software, in various aspects.
  • Compositions of matter disclosed herein include non-transient computer readable media operably received by the one or more computers to cause the one or more computers, at least in part, to function as the apparatus or to implement the steps of the methods of use.
  • a computer includes, a processor that may execute computer readable instructions operably received by the processor.
  • the computer may be, for example, a single- processor computer, multiprocessor computer, multi-core computer, minicomputers, mainframe computer, supercomputer, distributed computer, personal computer, hand-held computing device, tablet, smart phone, and a virtual machine, and the computer may include several processors in networked communication with one another.
  • the computer may include memory, screen, keyboard, mouse, storage devices, I/O devices, and so forth, in various aspects, that may be operably connected to a network.
  • the computer may execute various operating systems (OS) such as, for example, Microsoft Windows, Linux, UNIX, MAC OS X, real time operating system (RTOS), VxWorks, INTEGRITY, Android, iOS, or a monolithic software or firmware implementation without a defined traditional operating system.
  • OS operating systems
  • RTOS real time operating system
  • INTEGRITY Android, iOS, or a monolithic software or firmware implementation without a defined traditional operating system.
  • Network may include the Internet cloud, as well as other networks of local to global scope.
  • the network may include, for example, data storage devices, input/output devices, routers, databases, computers including servers, mobile devices, wireless communication devices, cellular networks, optical devices, cables, and other hardware and operable software, as would be readily recognized by those of ordinary skill in the art upon study of this disclosure.
  • Network may be wired (e.g. optical, electromagnetic), wireless (e.g. infra-red (IR), electromagnetic), or a combination of wired and wireless, and the network may conform, at least in part, to various standards, (e.g. Bluetooth®, FDDI, ARCNET IEEE 802.11, IEEE 802.20, IEEE 802.3, IEEE 1394-1995, USB).
  • FIG. 2 illustrates exemplary wound therapy apparatus 10.
  • wound interface 15 is secured to skin surface 11 to define enclosed space 17 that is fluid tight over a wound bed, such as wound bed 213, 313, 413.
  • wound therapy apparatus 10 includes gas source 82 and liquid source 84 in fluid communication with enclosed space 17 of wound interface 15.
  • wound therapy apparatus 10 includes control group 30, and control group 30 includes controller 87, user I/O 86, valve 88, pump 89, and pressure sensor 91.
  • Control group 30 regulates the communication of gas 22 from gas source 82, liquid 24 from liquid source 84, or combinations of gas 22 and liquid 24 into enclosed space 17 as input fluid 16, as illustrated.
  • Control group 30 regulates the withdrawal of output fluid 18 from enclosed space 17, and output fluid 18 may include, for example, input fluid 16 and exudate 19 as well as air evacuated from enclosed space 17 following attachment of wound interface 15 to skin surface 11 , as illustrated.
  • controller 87, user I/O 86, valve 88, pump 89, and pressure sensor 91 are grouped into control group 30 for explanatory purposes only, in this implementation, and that no spatial or other physical organization or proximity of controller 87, user I/O 86, valve 88, pump 89, and pressure sensor 91 with respect to one another or with respect to gas source 82, liquid source 84 or wound interface 15 is implied by virtue of being grouped into control group 30.
  • Controller 87 communicates operably with user I/O 86 via communication pathway 64 to communicate data 74 with user I/O 86. Controller 87 communicates operably with valve 88, pump 89, and pressure sensor 91 via communication pathways 61, 62, 63 to control operations of valve 88, pump 89, pressure sensor 91, respectively, at least in part in response to data 74 received by controller 87 from user I/O 86 in order to alter pressure po within enclosed space 17, for example, according to exemplary pressure cycle 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 (see Figures 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 91, 9J, respectively) by regulating the input of input fluid 16 into enclosed space 17 and the withdrawal of output fluid 18 from enclosed space 17.
  • Controller 87 may control operations of valve 88, pump 89, pressure sensor 91 at least in part in response to data 74 received from user I/O 86, for example, to deliver Therapy Regimen 1, 2, 3 or 4, to the wound bed enclosed by wound interface 15 ⁇ see Example 1).
  • the user may select the pressure cycle, such as pressure cycle 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, and the user may select the therapy regimen, such as Therapy Regimen 1, 2, 3 or 4, using user I/O 86.
  • Controller 87 controls the operation of wound therapy apparatus 10, at least in part, based upon data 74 communicated to controller 87 from user I/O 86. Controller 87 may control the operation of wound therapy apparatus 10, at least in part, based upon data 71, 72, 73 communicated between controller 87 and valve 88, pump 89, and pressure sensor 91, respectively.
  • Valve 88 and pressure sensor 91 are illustrated as a single valve and a single pressure sensor in this exemplary implementation for explanatory purposes. Is should be recognized that valve 88 may include one or more valves variously disposed about wound therapy apparatus 10 and that pressure sensor 91 may include one or more pressure sensors variously disposed about wound therapy apparatus 10, as would be readily recognized by those of ordinary skill in the art upon study of this disclosure.
  • Controller 87 may include, for example, a processor, memory, software operably communicating with the microprocessor, A/D converter, D/A converter, clock, I/O connectors, and so forth, and controller 87 may be configured for example, as a single chip or as an array of chips disposed about a circuit board, as would be readily recognized by those of ordinary skill in the art upon study of this disclosure.
  • controller 87 may be configured as software operatively received by a computer, and the computer may be, at least in part, located remote, for example, from valve 88, pump 89, and pressure sensor 91.
  • User I/O 86 may include various switches, push buttons, dials, sliders, graphs, and so forth, whether virtual or physical, for obtaining data 74 from the user that are then communicated to controller 87 in order to allow the user to direct the operation of wound therapy apparatus 10 including pressure cycles of pressure po within enclosed space 17 and the delivery of various therapy regimens.
  • user I/O 86 may be formed as software operably received by a computer. Controller 87 may communicate data 74 to user I/O 86 indicative of the operation of wound therapy apparatus 10, and user I/O 86 may display data 74 to the user.
  • gas source 82 fiuidly communicates gas 22 and liquid source 84 fiuidly communicates liquid 24 with enclosed space 17 of wound interface 15 as input fluid 16 controlled by controller 87 using valve 88.
  • valve 88 may select gas 22 from gas source 82, liquid 24 from liquid source 84, or combinations of gas 22 from gas source 82 and liquid 24 from liquid source 44 as input fluid 16 for input into enclosed space 17, and valve 88 may regulate, at least in part, the input of input fluid 16 into enclosed space 17 of wound interface 15.
  • Gas source 82 may be, for example, a cylinder of gas including oxygen, an oxygen bag, an oxygen generator, or mains gas including mains oxygen.
  • Liquid source 84 may be, for example, a container of liquid 24 or mains supply of liquid 24.
  • output fluid 18 withdrawn from enclosed space 17 passes through reservoir 81, and reservoir 81 captures exudate 19 or liquid, such as liquid 24, from output fluid 18 in chamber 99 of reservoir 81.
  • Gaseous portions of output fluid 18 or gas displaced from chamber 99 of reservoir 81 by capture of liquid 24 or exudate 19 therein may then be vented to the atmosphere from pump 89.
  • Valve 88, pump 89, or valve 88 in combination with pump 89 may regulate the withdrawal of output fluid 18 from enclosed space the quantity of exudate 19 is minimal or there is no liquid, such as liquid 24, in output fluid 18.
  • Liquid 24 may be withdrawn from enclosed space 17 at least in part by chamber pressure p r within chamber 99 of reservoir 81 when chamber pressure p r is less than ambient pressure p am b.
  • Chamber 99 which may be disposable and replaceable, provides storage for liquid 24 flowed through enclosed space 17 so that a volume of liquid 24 generally equal to the volume of chamber 99 may be flowed through enclosed space 17 and collected in chamber 99.
  • pump 89 is OFF and chamber pressure p r is less than ambient pressure p am b, the chamber pressure p r decreases toward ambient pressure p am b as liquid 24 withdrawn from enclosed space 17 is collected in chamber 99.
  • Liquid input into enclosed space 17 may be stopped, for example, when chamber pressure p r reaches some set point below ambient pressure pamb, say - 10mm Hg, or when liquid 24 fills a certain portion of chamber 99 in order to prevent excessive pressure pO within enclosed space 17 that may breach the sealing attachment of wound interface 15 to skin surface 1 1.
  • valve 88 operably communicates with gas 22, liquid 24, input fluid 16, and output fluid 18.
  • valve 88 may include one or more valves disposed about wound therapy apparatus to select input fluid 16 as gas 22, liquid 24, combinations of gas 22 and liquid 24, to regulate, at least in part, the input of input fluid 16 into enclosed space 17 of wound interface 15, and to regulate, at least in part, the withdrawal of output fluid 18 from enclosed space 17 of wound interface 15.
  • Data 71 may control the operation of valve 88 and data 71 may be indicative of the operation of valve 88. For example, data 71 may position valve 88 from an open position to a closed position, or data 71 may indicate that valve 88 is in the open position or in the closed position.
  • pressure sensor 91 operably communicates with gas 22, liquid 24, input fluid 16, and output fluid 18, and enclosed space 17.
  • Pressure sensor 91 may include one or more pressure sensors operable, for example, to detect pressure at various locations in gas 22, liquid 24, input fluid 16, output fluid 18, gas source 82, liquid source 24, or enclosed space 17 of wound interface 15.
  • Pressure sensor 91 may communicate data 73 indicative of the pressure at various locations in gas 22, liquid 24, input fluid 16, output fluid 18, gas source 82, liquid source 24, or enclosed space 17 to controller 87, and controller 87 may alter the operation of valve 88 or pump 89 in response to data 73 from pressure sensor 91.
  • controller may control valve 88 or pump 89 to maintain the actual pressure p a within enclosed space 17 generally between a minimum pressure p mm and a maximum pr6SSUr6 pmax and may vary the actual pressure pa within enclosed space 17 according to a pressure cycle, such as pressure cycle 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 as described in Figures 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 91, 9J, respectively.
  • a pressure cycle such as pressure cycle 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 as described in Figures 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 91, 9J, respectively.
  • control group may halt input of liquid 24 once the actual pressure p a reaches a preset value (such as - 20 mmHg) in order to prevent overflow of the enclosed space that may dislodge wound interface 15 from skin surface 11.
  • control group may regulate input of liquid 24 to maintain the actual pressure p a of liquid 24 in enclosed space 17 at a target pressure po (such as -20 mmHg or ambient pressure p am b) in order to prevent overflow of the enclosed space that may dislodge wound interface 15 from skin surface 11 when liquid 24 is simultaneously input as input fluid 16 and withdrawn as output fluid 18 from the enclosed space.
  • Data 73 may be communicated between controller 87 and pressure sensor 91 to control the sensing of pressure by pressure sensor 91, for example, the frequency of pressure sensing. Data 73 may be indicative of pressure as sensed by pressure sensor 91.
  • Input fluid 16 may be communicated under pressure of gas source 82 (e.g. , a tank of compressed gas), pressure of liquid source 84 (e.g. , piezometric head at liquid source), suction of pump 89, and combinations thereof.
  • Pump 89 may withdraw output fluid 18 from enclosed space 17.
  • Pump 89 may be, for example, a centrifugal pump, positive displacement pump, or peristaltic pump, in various implementations.
  • Data 72 for example, may be communicated from controller 87 to pump 89 to control a speed of pump 89 or data 72 may be indicative of the actual speed of pump 89 as communicated from pump 89 to controller 87.
  • Wound therapy apparatus 10 may include various fluid conveyances, for example hoses, pipes, valves, tubing, connectors, pressure regulators, plenums, and various other fittings, to communicate gas 22 and liquid 24 from gas source 82 and liquid source 84, respectively, to enclosed space 17 of wound interface 15 as input fluid 16 and to communicate output fluid 18 withdrawn from enclosed space 17 of wound interface 15.
  • Communication pathways 61, 62, 63, 64 may be, for example, wired, wireless, optical (e.g., fiberoptic, infrared), networked (e.g., Internet), or various combinations thereof, in various implementations.
  • Valve 88, pump 89, and pressure sensor 91 may include, for example, A/D converters, D/A converters, actuators, solenoids, stepper motors, microprocessors, to control the operations of valve 88, pump 89, and pressures sensor 91 using data 71 , 72, 73, respectively, or to communicated data 71 , 72, 73 to controller 87 indicative of the operation of valve 88, pump 89, and pressure sensor 91 , as would be readily recognized by those of ordinary skill in the art upon study of the present disclosure.
  • Data 71, 72, 73, 74 may be digital, analog, or combinations thereof, in various implementations.
  • One or more power source(s) may be disposed about wound therapy apparatus 10 in electrical communication with controller 87, valve 88, pump 89, and pressure sensor 91to flow electrical power thereupon.
  • the power source(s) may be, for example, mains electric, battery, or combinations of mains electric and battery, and the power source(s) may include, for example, a transformer, an inverter, a rectifier, filter(s), surge protector, as would be readily recognized by those of ordinary skill in the art upon study of the present disclosure.
  • FIGs 3A, 4A and Figures 3B, 4B illustrate exemplary wound therapy apparatus 100 in operational configurations 1 1 1, 113, respectively.
  • control group 130 includes reservoir housing 120 and control package 160 releasably secured to one another.
  • reservoir housing 120 has been removed from releasable securement to control package 160 so that control group 130 includes only control package 160 in operational configuration 1 13.
  • control group 130 may be operably configured as either reservoir housing 120 in releasable securement to control package 160 per operational configuration 1 11 , or control package 160 alone per operational configuration 1 13.
  • wound therapy apparatus 100 includes gas source 112, humidity source 1 14, wound interface 1 15 that defines enclosed space 1 17, and control group 130.
  • Control package 160 of control group 130 selects input fluid 116 as either gas 125 from gas source 1 12 plus humidity 129 from humidity source 1 14 or air 128 from atmosphere 127, and control package 160 controls the input of input fluid 116 into enclosed space 1 17 of wound interface 115, the withdrawal of output fluid 118 from enclosed space 1 17 of wound interface 115, and the exhausting of at least portions of output fluid 118 into the atmosphere, as illustrated in Figures 3A, 3B.
  • Wound therapy apparatus 100 includes various fluid conveyances, for example hoses, pipes, valves, tubing, connectors, plenum, reservoirs, and various other fittings, to communicate gas 125 from gas source 1 12 and air 128 from atmosphere 127 into enclosed space 1 17 as input fluid 1 16 and to communicate output fluid 118 between wound interface 1 15 and control group 130.
  • Input fluid 116 as air 128 from atmosphere 127 may be input into the enclosed space 1 17 to set actual pressure p a within the enclosed space 1 17 to ambient pressure p am b in the event of power failure of wound therapy apparatus 100.
  • reservoir housing 120 includes reservoir 150, and output fluid 118 withdrawn from enclosed space 117 passes through reservoir 150.
  • Reservoir 150 captures exudate 152 including other liquids from output fluid 1 18 in chamber 155 of reservoir 150, in the implementation of Figure 3A. Gaseous portions of output fluid 118 or gas displaced from chamber 155 of reservoir 150 by capture therein of exudate 152 may then be discharged to the atmosphere 127 from pump 189, as illustrated.
  • Reservoir 150 may be, for example, a canister, container, or space within reservoir housing 120 that may comprise substantially the interior of reservoir housing 120.
  • Reservoir 150 and reservoir housing 120 may be formed as a unitary structure in certain implementations. Reservoir 150 may be removable and replaceable in some implementations.
  • Reservoir 150 may be openable to allow reservoir 150 to be emptied and reused, in some implementations. In other implementations, reservoir 150 is sealed so as not to be reusable. In such implementations, reservoir housing 120 may functionally become the reservoir and may be replaced in its entirety. Accordingly, either reservoir 150, or reservoir housing 120 with or without reservoir 150, may be formed to be disposable. Chamber 155 of reservoir 150 may include a pad layer or pouch of super absorbent polymer to gel exudate 152. Odor neutralizing agents may optionally also be included in reservoir housing 120 including within chamber 155.
  • reservoir housing 120 has been removed from releasable securement to control package 160 and control group 130 includes only control package 160 in operational configuration 1 13.
  • Input fluid 1 16 flows under the control of control package 160 to wound interface 1 15, and output fluid 118 flows from wound interface 1 15 towards control package 160 without passage through reservoir housing 120 in operational configuration 1 13, as illustrated in Figure 2B.
  • Reservoir housing 120 may be disengaged from control package 160 placing control group 130 in operational configuration 1 13 because, for example, exudate 152 from the wound bed is low to non-existent, wound interface 1 15 retains exudate 152 within wound interface 115, or it is desirable for the patient to be unencumbered by reservoir housing 120.
  • Control group 130 may recognize the change in configuration and deliver therapies that are appropriate for the applicable corresponding configuration.
  • control package 160 includes power source 162 that may variously be, for example, a battery, mains electric, or a battery in combination with mains electric with the battery providing back-up power.
  • Power source 162 in various implementations, may include, for example, a transformer, inverter, and regulatory circuitry, as would be readily understood by those of ordinary skill in the art upon study of this disclosure. If power source 162 includes abattery, the battery may be, for example, nickel cadmium, nickel metal hydride, or lithium ion based.
  • Power source 162 is in electrical communication with various components of controller 60 including controller 165, pump 168, valves 172, 173, 174, pressure sensor 176, pressure sensor 178, and user I/O 145 to flow power thereto, in this implementation.
  • Various electrical pathways may be disposed about control group 130 to communicate electrical power from power source 162 to controller 165, pump 168, valves 172, 173, 174, pressure sensors 176, 178, and user I/O 145.
  • Pump 168 may be, for example, a rotary pump or a positive displacement pump, in various implementations.
  • Valves 172, 173, 174 may be electromechanically actuated by, for example, solenoid or stepper motor.
  • valves 172, 173, 174 may be configured as a three-way valve or as a combination of valves, in various implementations. While this implementation includes pressure sensors 176, 178, other implementations may include a single pressure sensor that functions as the combined pressure sensors 176, 178 or senses pressures of different locations. Other implementations of control group 130 may include various numbers of valves, such as valves 172, 173, 174 that work in conjunction with various numbers of pressure sensors, such as pressure sensors 176, 178, to measure and regulate the pressure(s), leading up to, within, or downstream from, a compartment or housing. Such multi-point sensing may enable a more intelligent differential monitoring and diagnosis of a system or fault condition and may pin point the location and nature of a condition to facilitate troubleshooting, adjustment, or corrective action.
  • Controller 165 controls, at least in part, the operation of wound therapy apparatus 10 including control group 130, in this implementation.
  • Controller 165 may include, for example, a microprocessor, memory, A/D converter, D/A converter, clock, I/O connectors, and so forth, as would be readily recognized by those of ordinary skill in the art upon study of this disclosure.
  • Controller 165 may communicate with power source 162 to monitor power source 162, to receive power from power source 162, or to regulate the flow of power from power source onto pump 168, valves 172, 173, 174, pressure sensors 176, 178, and user I/O 145.
  • Controller 165 may communicate operatively with pump 168, valves 172, 173, 174, pressure sensors 176, 178 to regulate the operation thereof.
  • Controller 165 may communicate operatively with pump 168, valve 172, valve 174, pressure sensors 176, 178 to receive information from pump 168, valves 172, 173, 174, pressure sensors 176, 178 indicative of the operation thereof or indicative of the operation of wound therapy apparatus 100.
  • User I/O 145 which may be placed exteriorly about control group 130 or remotely from control group 130, may include a display for the display of the operational status of wound therapy apparatus 100 to a user.
  • User I/O 145 may include various switches, push buttons, dials, and so forth, whether virtual or physical for obtaining user inputs to allow the user to regulate the operation of wound therapy apparatus 100 including control group 130.
  • User I/O 145 and controller 165 may communicate with one another to communicate user inputs from user I/O 145 to controller 165 to regulate the operation of wound therapy apparatus 100 including control group 130 and to communicate information from controller 165 to user I/O 145 indicative of operations of wound therapy apparatus 100.
  • Various communication pathways such as wired, optical (e.g. LASER, IR), and network may be included about wound therapy apparatus 10 including control group 130 for communication between controller 65 and pump 68, valve 72, valve 73, valve 74, pressure sensors 76, 78, and user I/O 45.
  • control group 130 for communication between controller 65 and pump 68, valve 72, valve 73, valve 74, pressure sensors 76, 78, and user I/O 45.
  • at least portions of user I/O 145 may be remote from the remainder of control group 130, such as on a smart phone application, and user I/O 145 may communicate with controller 165 by various networks that may be wireless, at least in part.
  • User I/O 145 may interface with a network such as the Internet by wired or wireless connection to communicate data indicative of operations of wound therapy apparatus 100 via networked communication or to receive inputs that regulate operations of wound therapy apparatus 100.
  • control group 130 includes control package 160, and control package 160 includes power source 162, controller 165, pump 168, valves 172, 173, 174 pressure sensors 176, 178, and user I/O 145.
  • Reservoir housing 120 has been removed from engagement with control package 160, in operational configuration 113, so that control group 130 includes control package 160 and excludes reservoir housing 120, as illustrated in Figure 3B.
  • Wound therapy apparatus 100 may be placed in operational configuration 1 11, as illustrated in Figure 3 A.
  • wound interface 15 is secured to a skin surface 111 to enclose a wound bed, such as wound bed 113, 213, 313, within enclosed space 117 that is fluid tight.
  • Wound interface 15, control group 130 including both reservoir housing 120 and control package 160, humidity source 114, and gas source 112 are then placed in fluid communication with one another, as indicated in Figure 3A.
  • Wound therapy apparatus may be placed in operational configuration 111 when the wound bed is exuding exudate 152, for example, in early stages of wound therapy, because operational configuration 111, as illustrated in Figures 3A, 4A, includes reservoir 150 for the collection of exudate 152.
  • gas 125 from gas source 1 12 combined with humidity 129 from humidity source 114 is in communication with valve 174 through connector 182 of control group 130, and air 128 from atmosphere 127 is in communication with valve 173 through port 183 of control package 160. Note that, in Figures 4A, 4B, the path of input fluid
  • Input fluid 1 16 may be selected as either air 128 or gas 125 including humidity 129 or by operation of valves 173, 174. Controller 165 may operate valve 174 to select gas 125 plus humidity 129 as input fluid 1 16, or controller 165 may operate valve 173 to select air 128 as input fluid. Input fluid 1 16 then flows either from valve 173 or from valve 174, through connector 184 of control group 130, and thence into the enclosed space 117 of the wound interface 1 15.
  • gas source 112 may include multiple gas sources that may supply a variety of gasses and combinations of gasses as gas 125, and the composition of gas 125 may vary during the course of wound therapy. The user may variously select the composition of gas 125 for use during various times of wound therapy.
  • pressure sensor 176 is in operable communication with enclosed space 117 including input fluid 1 16 as input fluid 116 is being input into enclosed space 1 17 to detect the actual pr6SSUr6 pa within the enclosed space 117, in this implementation.
  • the actual pressure pa within enclosed space 1 17 as detected by pressure sensor 176 is communicated from pressure sensor 176 to controller 165, and controller 165 may position either valve 173 or valve 174 to regulate flow of input fluid 1 16 into the enclosed space 117 in order to cause actual pressure p a to proximate the target pressure po within the enclosed space
  • Pressure sensor 178 is in operable communication with enclosed space 117 including output fluid 116 as output fluid 118 is being withdrawn from enclosed space 1 17 to detect the actual pressure pa within the enclosed space 1 17, in this implementation.
  • the actual pressure p a within the enclosed space as detected by pressure sensor 178 may be communicated from pressure sensor 178 to controller 165, and controller 165 may position valve 172, regulate pump 168, or both position valve 172 and regulate pump 168 in order to regulate flow 1 18 from the enclosed space, and, thus, cause actual pressure p a to proximate the target pressure po within the enclosed space 1 17 (i.e., make p a ⁇ po).
  • output fluid 1 18, withdrawn, at least in part, by pump 168 flows from the enclosed space of wound interface 115 through connector 186 of control group 130, through reservoir 150, towards filter 124, towards connector 188 between reservoir housing 120 and control package 160, towards pump 168 under the control of valve 172.
  • Exudate 152 including other liquids is retained in chamber 155 as output fluid 118 flows through chamber 155 of reservoir 150, and exudate 152 including other liquids may also be captured by filter 124 as output fluid 118 as output fluid 118 passes through filter 124, as illustrated.
  • the remaining gaseous portions of output fluid 118 are then exhausted into the atmosphere on the discharge side of pump 168, as illustrated.
  • Filter 124 prevents exudate 152 including other liquid in output fluid 118 from reaching control package 160 including pump 168, thereby serving a protective function.
  • filter 124 may include a hydrophobic ultra-high molecular weight polyethylene (UHMW-PE) that may optionally be impregnated with carboxymethyl cellulose.
  • Filter 124 may include a hydrophobic filter material may comprise of sintered PTFE with optional addition of a super absorbent polymer such as sodium polyacrylate, or sodium carboxymethyl cellulose.
  • filter 124 When exudate 152 reaches filter 124, filter 124 clogs and expands abruptly, for example, increasing the pressure detected by pressure sensor 178, that, in turn, may trigger a protective shutoff of pump 168 by controller 165.
  • Filter 124 may be replaceably received within reservoir housing 120, or filter 124 may be omitted, in various implementations.
  • valve(s) such as valves 172, 173, 174, and pressure sensor(s), such as pressure sensors 176, 178, may be used in combination with controller 165 to regulate the flow of input fluid 1 16 into the enclosed space 117 or to regulate the flow of output fluid 1 18 from the enclosed space 117 in order to cause actual pressure p a to proximate target pressure po within the enclosed space.
  • valves 173 174 may be replaced with a three-way valve that selectable between no flow, flow of air 182, or flow of gas 125 including humidity 129.
  • wound therapy apparatus 100 may be placed in operational configuration 1 13, as illustrated in Figures 3B, 4B.
  • wound interface 1 15 is secured to skin surface 11 1 to enclose a wound bed, such as wound bed 213, 313, 413, within enclosed space 117 that is fluid tight.
  • Wound therapy apparatus 100 may be placed in operational configuration 1 13, as illustrated in Figures 3B, 4B when the wound bed is no-longer exuding exudate 152, for example, in later stages of healing of the wound bed.
  • Operational configuration 113 excludes reservoir 150 including reservoir housing 120 from control group 130, as reservoir 150 including reservoir housing 120 may not be needed, in this implementation.
  • Filter 124 may be included in controller group 130 in operational configuration 113 to capture stray liquids, in certain implementations.
  • output fluid 118 propelled, at least in part, by pump 168, flows from the enclosed space 117 of wound interface 115 through connector 188 of control package 160 of control group 130, through valve 172, and through pump 168. Output fluid 118 is then exhausted into the atmosphere on the discharge side of pump 168, in this implementation.
  • Input fluid 116 may flow from either gas source 112 or atmosphere 127 to the enclosed space of wound interface 1 15 in operational configuration 113 as described with respect to operational configuration 111 illustrated in Figures 3 A, 4A.
  • controller 165 interacts with valves 172, 173, 174, pressure sensors 176, 178, and pump 168 to control the flow of input fluid 116 and output fluid 118, for example, in order to cause actual pressure p a to proximate target pressure po within the enclosed space or to deliver air 128 to the wound bed.
  • Connector 188 forms a point of attachment between reservoir housing 120 and control package 160 so that reservoir housing 120 and control package 160 are removably secured to one another at least at connector 188 in operational configuration 111.
  • Connector 188 forms a fluid pathway for flow of output fluid 118 from reservoir housing 120 to control package 160 when reservoir housing 120 and control package 160 are removably secured to one another in operational configuration 111.
  • Reservoir housing 120 is absent from control group 130 in operational configuration 113, and connector 188 provides a point for attachment of fluid conveyances between wound interface 115 and control package 160 to convey output fluid 118, in operational configuration 1 13.
  • Connectors 182, 184, 186 provide points of attachment for various fluid conveyances to control group 130 that allow input fluid 116 and output fluid 118 to flow therethrough, in this implementation.
  • Reservoir housing 120 may be removed from securement to control package 160 by disconnection at least at connector 188, and a new reservoir housing 120 may be removably secured to control package 160 at least by securement at connector 188, in this implementation.
  • reservoir housing 120 may be removed from securement to control package 160 by disconnection of at least at connector 188, and fluid conveyances between wound interface 115 and control package 160 may be secured to connector 188 thereby placing wound therapy apparatus 100 from operation configuration 1 11 into operational configuration 1 13, in this implementation.
  • controller 165 is in operable communication with valves 172, 174, pressure sensors 176, 178, and pump 168 to vary actual pr6SSUr6 pa within enclosed space 117 generally over the pressure range p mm ⁇ p a ⁇ p ma x in correspondence to target pressure po that may vary periodically within the pressure range p mm ⁇ po ⁇ p ma x where p mm is the minimum value of target pressure po and pmax is the maximum value of target pressure po.
  • p mm ⁇ p am b where p am b is the ambient pressure of atmosphere 127 proximate wound therapy apparatus 100.
  • the minimum pressure may be, for example, pmm ⁇ pamb - 130 mm Hg.
  • the minimum pressure may be, for example, p m m ⁇ p am b - 90 mm Hg.
  • the minimum pressure p m m may be, for example, within the pressure range (pamb - 130 mm Hg) ⁇ pmm ⁇ ( pamb - 90 mm Hg).
  • the minimum pressure p m m may be generally within the pressure range (p am b - 90 mm Hg) ⁇ p m tn ⁇ p am b.
  • the periodic variation of the target pressure po may be generally within the pressure range p m m ⁇ po ⁇ pmax where pmax > p am b.
  • pmax ⁇ (pamb +40 mm Hg).
  • the maximum pressure pmax may be slightly less than ambient pressure p am , for example, generally within the range of p am b - 5 mm Hg to p am b - 20 mm Hg.
  • Figure 5 illustrates exemplary operational states 132, 134, 136 of wound therapy apparatus 100 as target pressure po is varied periodically within the pressure range p m m ⁇ po ⁇ pmax, and wound therapy apparatus 100 may be varied between operational states 132, 134, 136 to cause the actual pressure p a to correspond to target pressure po.
  • Operational states 132, 134, 136 are exemplary, not limiting, so that wound therapy apparatus 100 may be placed in operational states other than operational states 132, 134, 136.
  • wound therapy apparatus varies sequentially between operational states 132, 134, 136 so that, for example, operational states 132, 136 do not exist simultaneously.
  • Figure 5 excludes humidity source 114, and reservoir 150 for clarity of explanation, so that Figure 5 is illustrative of the operation of wound therapy apparatus 100 in both operational configurations 1 1 1, 113.
  • Valve l 73 which is also omitted from Figure 5 for clarity of explanation, is in the CLOSED position in exemplary operational states 132, 134, 136 illustrated in Figure 5.
  • output fluid 118 is being withdrawn from enclosed space 117 of wound interface 1 15 to vary the actual pressure p a in correspondence with target pressure po toward minimum pressure pmin in order to achieve Pa ⁇ PO— Pmin or to remove exudate 152 from the enclosed space 117.
  • Pump 168 may be in an ON condition in operational state 132.
  • Output fluid 118 flows from enclosed space of wound interface 1 15 through valve 172, which is in an OPEN position, propelled by pump 168, and gaseous portions of output fluid 1 18 are discharged into the atmosphere 127 by pump 168, as illustrated.
  • Valve 174 is in a CLOSED position, so that no input fluid 1 16 is being input into enclosed space of wound interface 115 in operational state 132, as illustrated.
  • Pressure sensor 178 is in operative communication with the enclosed space of wound interface 1 15 to detect actual pressure pa within the enclosed space 117 including output fluid 118, in this implementation.
  • the actual pressure p a detected by pressure sensor 178 may be communicated from pressure sensor 178 to controller 165, and controller 165 may position valve 172 between OPEN position and CLOSED position including positions intermediate of OPEN position and CLOSED position to achieve p a ⁇ po as target pressure po is decreased toward p mm .
  • Controller 165 may adjust operations of pump 168 including, for example, the speed of pump 168 in order to achieve p a ⁇ po and to achieve
  • valves 172, 174 are both in CLOSED position, so there is generally no input of input fluid 116 into enclosed space 117 or withdrawal of output fluid 1 18 out of enclosed space 117.
  • valves 172, 174 are both in CLOSED position, so there is generally no input of input fluid 116 into enclosed space 117 or withdrawal of output fluid 1 18 out of enclosed space 117.
  • pressure sensor 176, pressure sensor 178, or both pressure sensors 176, 178 may detect actual pressure pa within enclosed space of wound interface 1 15, and the actual pressure p a detected by pressure sensor 176, 178 may be communicated from pressure sensor 176, 178 to controller 165.
  • Controller 165 may position valves 172, 174, alter pump 168 between the OFF state and the ON state, or adjust the operation of pump 168 or valves 172, 174 intermittently, for example, in order to maintain p a ⁇ po ⁇ pmm, to maintain p a ⁇ po ⁇ pmax, or to withdraw exudate 152 from the enclosed space 117 of wound interface 1 15 as needed, in exemplary operational stage 134.
  • exemplary operational state 136 as illustrated in Figure 7 (indicated by dashed line), input fluid 1 16 is being input into enclosed space 1 17 of wound interface 1 15 to vary the actual pressure p a in correspondence with the target pressure po toward maximum pressure pmax in order to achieve Pa ⁇ PO ⁇ Pmax.
  • Input fluid 1 16 flows into enclosed space 117 of wound interface 115 through valve 174, which is in OPEN position, and the flow of input fluid 1 16 into the enclosed space 117 is driven by pressure p s at gas source 112, in this implementation.
  • Valve 172 is in CLOSED position, so that there is no output fluid 1 18 being withdrawn from enclosed space 117 of wound interface 115 while input fluid 116 is being input into enclosed space 117 in operational state 136.
  • Pressure sensor 176 is in operative communication with the enclosed space 117 of wound interface 115 including input fluid 116 to detect actual pressure pa within the enclosed space 117 of wound interface 1 15 at operational state 136, in this implementation.
  • the actual pressure p a detected by pressure sensor 176 may be communicated from pressure sensor 176 to controller 165, and controller 165 may position valve 174 between OPEN position and CLOSED position including positions intermediate of OPEN position and CLOSED position in order to achieve p a ⁇ po as target pressure po is increased toward p ma x.
  • Pump 168 may be in an OFF condition in operational state 136.
  • valves 172, 174 are positioned between the OPEN position and the CLOSED position to sequentially input the input fluid 1 16 into enclosed space 117 and withdraw output fluid 118 from the enclosed space 117, meaning that withdrawal of output fluid 118 and the input of input fluid 116 does not occur simultaneously.
  • Input fluid 116 may be being input into the enclosed space or output fluid 1 18 may be being withdrawn from the enclosed space but not the input of input fluid 116 simultaneously with output of output fluid 118, in this illustrated implementation.
  • valve 172 may be in the OPEN position simultaneously with valve 174 in the CLOSED position, valve 172 may be in the CLOSED position simultaneously with valve 174 in the OPEN position, or valve 172 may be in the CLOSED position simultaneously with valve 174 in the CLOSED position, but valves 172, 174 are never both in the OPEN position at the same time, in this illustrated implementation.
  • Pressure sensor 176 or other pressure sensor(s) disposed about control group 130 may, for example, detect that pressure p s at gas source 112 is below some minimum value indicating that gas source 112 is exhausted. As another example, control group 130 may be disconnected from gas source 112. Valve 174 may then be placed in the CLOSED position, and valve 173 may be altered between CLOSED position and OPEN position in lieu of valve 174 in order to alter wound therapy apparatus between operational states 132, 134, 136. Air 128 from atmosphere 127 as regulated by valve 173 is then input into enclosed space 117, for example to vary the actual pressure p a in correspondence with the target pressure po toward maximum pressure p ma x.
  • FIGS 6A and 6B illustrate wound therapy apparatus 200 at exemplary first stage of operation 236 and at exemplary second stage of operation 238, respectively.
  • wound therapy apparatus 200 includes wound interface 215 that is deformation resistant and defines enclosed space 217 that is fluid-tight to enclose wound bed 213 at skin surface 211 when wound interface 215 is engaged with skin surface 21 1.
  • Wound interface 215, as illustrated, includes cover 240 slidably sealingly frictionally removably engaged with base 220.
  • Cover 240 may include at least transparent portions to allow visual inspection of wound bed 213 though cover 240.
  • Base 220 may include flange 209 around at least portions of an outer perimeter of base 220 that may provide structural support or sealing surface against cover 240, as illustrated.
  • cover 240 and base 220 may be formed as a unitary structure or cover 240 may be engaged hingedly or engaged in other ways with base 220.
  • wound interface 215 is illustrated as cylindrical in shape enclosing a circular region of skin surface 21 1, it should be understood the structure, such as wound interface 215, may assume other geometric shapes to enclose other geometrically shaped regions of skin 21 1 such as rectangular, polygonal, or ovoid, to enclose various shaped wounds, and may include other modifications such as to base 220 to fit skin surface 211 in various regions of the body, in various other implementations.
  • one or more additional ports in communication with enclosed space 217 may be situated about the wound interface 215 for monitoring parameters within enclosed space 217, communication of fluids with enclosed space 217, or other therapeutic interventions with enclosed space 217.
  • Base 220 in this implementation, includes flange 229 around the entire perimeter of outer side 223 of base 220 generally at distal end 222 of base 220.
  • Flange 229 is secured to skin surface 211 by adhesive 290, as illustrated in Figures 6A, 6B, around the entire perimeter of base 220 to form fluid-tight enclosed space 217, and wound boundary 212 is enclosed within enclosed space 217.
  • Flange 229 may be designed by thickness and/or polymeric material to be soft and conformable to enable sealing of wound interface 215 over a wound 213 in a fluid- tight manner while distributing forces on wound interface 215 from actual pressure pa within enclosed space 217 over the skin surface 211.
  • Adhesive layer 290 may optionally extend over portions of skin surface 21 1 to include all skin surface under and proximate to flange 229 at distal end 222.
  • the adhesive is a medically suitable member of the cyanoacrylate class, such as N-butyl-2-cyanoacrylate (Histoacryl Blue), or octyl-2-cyanoacrylate (Dermabond)
  • the layer of water-resistant adhesive coating over the peri-wound skin surface serves the additional function of protecting the normal skin from maceration, secondary to prolonged exposure to other fluids, such as exudate, proteolytic enzyme soaks or saline lavages, etc.
  • wound interface 215 may be formed of any of various medical polymers including, for example, polycarbonate, polystyrene, polypropylene or ABS; and may further be associated with additional sealing structures such as an inflatably adjustable circumferential cushion between the base and the adhesive layer around the perimeter of the wound bed.
  • Port 242 which is located about wound interface 215, is in fluid communication with enclosed space 217 via lumen 245, in this implementation.
  • Lumen 245 of port 242 may be in fluid communication with a control group, such as control group 30, 130 of wound therapy apparatus 10, 100, respectively, and the control group may control the input of input fluid 216 into enclosed space 217 or the withdrawal of output fluid 218 from enclosed space 217 via lumen 245, in this implementation.
  • Input fluid 216 may be input into enclosed space 217 via lumen 245 of port 242, as indicated by the arrow in Figures 6A, 6B, for example, to regulate, at least in part, the actual pressure pa within enclosed space 217, to control the composition of the gaseous fluids within enclosed space 217, or for various therapeutic purposes.
  • Input fluid 216 may be input into enclosed space 217 to increase the actual pressure pa within enclosed space 217 in conformance to increases in the target pressure po.
  • Input fluid 216 may include gas, such as gas 22, 125, gas 22, 125 plus humidity 129 from a humidity source, such as humidity source 114.
  • Input fluid may include liquid, such as liquid 24.
  • Output fluid 218 may include input fluid 216 and output fluid 218 may include exudate 252, so that output fluid 218 may include liquid, gas, and combinations of liquid and gas from within enclosed space 217.
  • Input fluid 216 or output fluid 218 may include liquid, such as liquid 24, that may have various therapeutic purposes.
  • Output fluid 218 is withdrawn from enclosed space 217 through lumen 245 of port 242, as illustrated, for example, to decrease the actual pressure pa within enclosed space 217 in conformance to decreases in the target pressure po, to remove exudate 252 from enclosed space 217, or to remove liquid, such as liquid 24, from enclosed space 217.
  • a pad 250 may be deployed within enclosed space 217 to absorb and transfer exudate 252 away from wound bed 213, and the pad 250 may be in fluid communication with port 242 to allow withdrawal of exudate 252 from wound bed 213 through the pad 250 and thence through port 242.
  • Pad 250 may be formed of materials with absorbent and fluid transfer properties so as to absorb exudate. These materials include, for example, open-cell foam composed, for example, of polyvinyl alcohol (PVA), polyurethane or other polymer foam.
  • Pad 250 may be formed of various woven or non-woven fibers such as sodium carboxymethyl cellulose hydrofiber (Aquacel), or knitted fibers with hydrophobic polyester fiber predominant on outer surface and hydrophilic nylon fibers predominantly on the inside to serve as a conduit to fluid transfer.
  • the hydrophobic polyester fiber wicks away liquid and prevents moisture buildup and secondary maceration of tissue with which pad 250 is in sustained contact.
  • a super absorbent polymer such as sodium polyacrylate
  • SAP super absorbent polymer
  • a quantity of SAP is added to a closed-cell polyurethane may enable passage of liquid through the resulting matrix, thereby enhancing the absorbent and fluid transfer properties of the matrix.
  • Wound therapy apparatus 200 may be periodically varied between first stage of operation 236 and second stage of operation 238 by consecutive withdrawal of output fluid 218 from enclosed space 217 and input of input fluid 216 into enclosed space 217 via lumen 245 of port 242.
  • the maximum pressure may be generally equal to ambient pressure p am b (i. e., p ma x ⁇ p am b)
  • the actual pressure p a generally equals the target pressure po (i. e., p a ⁇ po) within enclosed space 217.
  • Wound bed 213 is in a baseline state 293, and is in spaced relation with pad 250 such that there is reduced contact or no contact between pad 250 and wound bed 213.
  • the gap, if any, between pad 250 and wound bed may vary depending on the shape, structure and material used to make pad 250.
  • wound interface 215 defines entry 226 to enclosed space 217, and the portions of wound bed 213 enclosed by enclosed space 217 may generally lie outside entry 226 in baseline state 293.
  • Capillary 296, which is proximate wound bed 213, is undilated in baseline condition 297 and conveys a baseline quantity of blood to wound bed 213 in baseline condition 297 at first stage of operation 236, as illustrated in Figure 6A.
  • Pressure pmm is less than ambient pressure p am b (i. e. p mm ⁇ p am b ) by an amount sufficient to cause at least portions of wound bed 213 to be distended into enclosed space 217 through entry 226 in distended state 294.
  • Pad 250 may thus effectively absorb and transfer exudate from wound bed 213 through lumen 245 as at least a portion of output fluid 218 at second stage of operation 238.
  • Pad 250 fluidly communicates with lumen 245 of port 242 so that exudate may be evacuated through and from pad 250 through lumen 245 as at least a portion of output fluid 218 via external suction applied to port 242.
  • Capillary vessels proximate the wound bed, such as capillary 296, may be in a dilated state 298 when wound bed 213 is in distended state 294 at second stage of operation 238, as illustrated in Figure 6B.
  • a problem for example, is the clogging of the output tubing by exudate, leading to a falsely reassuring reading of target suction pressure being maintained by the control package when a much lower actual suction pressure, if any, exists at the wound site.
  • an additional port that is also in independent communication with enclosed space 217, differential pressure readings can be obtained of the same enclosed space from the front end and back end of a pressure conduit system that may enable more accurate diagnosis, and may localize problem situation to allow more targeted solutions or prophylactic actions.
  • the additional port may be situated a distance apart from the first port, with both ports in fluid communication with the wound.
  • such sudden one-way pressure relief may serve to blast purge exudate out of the suction port, from one end of the wound bed to the other, unclog tubing, maintain tubing patency, and help to maintain effective therapy.
  • Using an irrigant as a liquid bolus provided added benefit of further rinses away any condensed exudate, cellular debris and keep lines open.
  • intermittent use of irrigant to relieve suction may extend the clinically serviceable life of such a dressing system not unlike a self-cleaning diaper in that exudate and cellular debris is rinsed away and the dressing is "refreshed".
  • other benefits may include a lower incidence of adhesive tape allergy which is often precipitated by the repeated and concomitant loss of a layer of epidermis with each dressing change; the epidermal layer insulates the underlying dermis layer from being exposed to the adhesive.
  • FIG. 7 illustrates wound therapy apparatus 300 including wound interface 315.
  • Appliance 300 includes structure 315, and structure 315 includes covering 320 attached to skin surface 311 by adhesive 390 to enclose wound bed 313 at skin surface 311, with the entirety of wound boundary 312 covered by covering 320.
  • Distal side 322 of covering 320 faces wound bed 313 with covering 320 in securement to skin surface 311 by adhesive 390 on at least portions of distal side 322 of covering 320, thereby defining portions of enclosed space 317.
  • Enclosed space 317 includes at least portions of wound bed 313, as illustrated.
  • Dressing 350 is placed against wound bed 313 and sealingly covered by covering 320, as illustrated, so that dressing 350 lies within enclosed space 317, as illustrated.
  • ports 342, 344 are in fluid communication with enclosed space 317 between distal side 322 of covering 320 and proximal side 324 of covering 320 by lumen 345, 347, respectively.
  • Lumen 345, 347 in fluid communication with a control group, such as control group 30, 130 of wound therapy apparatus 10, 100, respectively, and the control group may regulate the input of input fluid 316 into enclosed space 317 through lumen 345 and regulate the withdrawal of output fluid 318 from enclosed space 317 through lumen 347, in this implementation.
  • Exudate 352 migrates from wound bed 313 into dressing 350, and exudate 352 may be withdrawn from dressing 350 as part of output fluid 318, in this implementation.
  • input fluid 316 may be input into enclosed space 317 via lumen 347 of port 342 and output fluid 318 may be withdrawn from enclosed space 317 via lumen 345 of port 344 as actual pressure p a within enclosed space 317 is varied in conformance to target pressure po.
  • target pressure po may be periodically varied over the pressure range pmin ⁇ po ⁇ pmax where pmin is the minimum target pressure over the pressure cycle and p ma x is the maximum target pressure over the pressure cycle, and the actual pressure p a is conformed to the target pressure po.
  • FIG. 8 illustrates exemplary wound therapy apparatus 400.
  • wound therapy apparatus 400 includes wound interface 415, and wound interface 415 includes member 420 with adhesive 490 coated on at least portions of distal surface 422 of member 420 for securing member 420 to skin surface 411.
  • distal surface 422 of member 420 encloses wound bed 413 at skin surface 411 within enclosed space 417.
  • Member 420 may be formed of various polymers such as, for example, polyurethane. Member 420 may be fluid-tight and member 420 may be deformation resistant.
  • flange 414 of port 442 secures port 442 to member 420 for fluid communication with enclosed space 417 by lumen 445.
  • the flange may be adhesively secured to the underside of pad 420 via an aperture in pad 420 as shown, or it may be adhesively secured on the upper and outer surface of member 420 and fluidly communicate with the enclosed space 437 within the wound interface via an aperture or connecting passageway.
  • Input fluid 416 may be input into enclosed space 417 via lumen 445 of port 442 and output fluid 418 may be withdrawn from enclosed space 417 via lumen 445 of port 442.
  • Lumen 445 may be in fluid communication with a control group, such as control group 30, 130 of wound therapy apparatus 10, 100, respectively.
  • the control group may regulate the input of input fluid 416 into enclosed space 417 through lumen 445 and regulate the withdrawal of output fluid 418 from enclosed space 417 through lumen 445, in this implementation, for example, to conform actual pressure p a with target pressure po as target pressure po within enclosed space 417 is, for example, periodically varied according to a pressure cycle generally having a pressure range p mm ⁇ po ⁇ p ma x where p m m is the minimum target pressure over the pressure cycle and p ma x is the maximum target pressure over the pressure cycle.
  • appliance 400 includes layers 460, 470, and 480 within enclosed space 417. Portions of layer 480, as illustrated, are secured to distal side 422 of member 420, and portions of distal side 482 of layer 480 are biased against skin surface 41 1 and wound bed 413.
  • Layer 470 is biased between layer 480 and layer 460 with distal side 472 of layer 470 biased against proximal side 484 of layer 480, and proximal side 474 of layer 470 biased against distal side 462 of layer 460.
  • Layer 460 is biased between layer 470 and spacer 430 with proximal side 474 of layer 470 biased against distal side 432 of spacer 430.
  • layers 460, 470, 480 may be included in other implementations of appliance 400, and the layers may be arranged in various ways, or certain layers omitted, depending on application. Different layers may have special characteristics and functions, such as, for example, liquid absorption, fluid transfer, and release of therapeutic substances.
  • Spacer 430 defines void 437 within spacer 430, and spacer 430 maintains layers 460, 470, 480 in biased engagement with one another, as illustrated.
  • Spacer 430 may generally be a bilayer polymer pouch with or without additional distribution channels within that may be created by localized bonding or welding 464. It may optionally be welded at multiple points 464 in the bilayer space to limit distension of the void 437 when under pressure. The purpose of spacer 430 is to disperse input fluid 416 across the entire wound surface.
  • Spacer 430 may have a variety of sizes and shapes such as circular, rectangular, ovoid, or starburst, with a perimeter that substantially approximates that of proximal side 464 of layer 460.
  • Lumen 445 passes through port 442 and through proximal side 434 of spacer 430 into void 437, and input fluid 416 may be communicated via lumen 445 into void 437 or output fluid 418 may be communicated from void 437 through lumen 445.
  • input fluid 416 may be communicated into void 437 through lumen 445, and input fluid 416 may then disperse within void 437 so that essentially the same pressure actual pressure p a exists throughout void 437.
  • Input fluid 416 may then flow from void 437 through spacer passages in distal side 432 of spacer 430, such as spacer passage 435, into layer 460.
  • the spacer passages may be evenly distributed over distal side 432 of spacer 430 so that input fluid 416 is evenly distributed over proximal side of layer 460 from void 437.
  • Input fluid 416 may then flow through layer 460, through layer 470, and through perforations, such as perforation 485, in layer 480 to contact wound bed 413 as well as skin surface 411.
  • the perforations which pass between proximal side 484 and distal side 482 of layer 480, may be evenly distributed over layer 480 so that input fluid 416 is evenly distributed over skin surface 411 and wound bed 413.
  • input fluid 416 may, for example, provide enhanced O2 exposure, antibiotic rinse, or cytokines in the form of amniotic fluid to wound bed 413 and to skin surface 411.
  • the actual pr6SSUr6 a exists throughout enclosed space 417 including wound bed 413 and skin surface 411, and input fluid 416 and output fluid 418 may flow throughout enclosed space 417 including layers 460, 470, 480 and through spacer 430.
  • the spacer 430 may optionally be structured more distally to be closer to or even adjacent the wound surface, in which case, spacer passages 435 may be present in both the distal and proximal sides of spacer 430.
  • Exudate 452 may flow from wound bed 413 through layer passages, such as layer passages 485 in layer 480, into layer 470, from layer 470 into layer 460, and from layer 460 through spacer passages, such as spacer passage 435, into void 437.
  • Output fluid 418 including exudate 452 may flow from layers 480, 470 460 through spacer passages 435 into void 437, and output fluid 418 may be withdrawn from void 437 through port 442 via lumen 445, in this implementation.
  • layer 480 is formed of silicone, including similar materials with scar modulation properties, and wound bed 413 has the form of an incision with stitch 499.
  • Silicone as used herein, includes siloxane, various polysiloxanes, silicone-like materials, and various combinations thereof that may be generally solid. Silicone may have the chemical formula
  • Examples may include, but are not limited to, crosslinked siloxanes (e.g., crosslinked dimethicone or dimethicone derivatives), copolymers such as stearyl methyl-dimethyl siloxane copolymer, polysilicone-1 1 (a crosslinked silicone rubber formed by the reaction of vinyl terminated silicone and (methylhydro dimethyl)polysiloxane in the presence of cyclomethicone), cetearyl dimethicone/vinyl dimethicone crosspolymer (a copolymer of cetearyl dimethicone crosslinked with vinyl dimethyl polysiloxane), dimethicone/phenyl vinyl dimethicone crosspolymer (a copolymer of dimethylpolysiloxane crosslinked with phenyl vinyl dimethylsiloxane), and dimethicone/vinyl dimethicone crosspolymer (a copolymer of dimethylpolysiloxane crosslinked with vinyl dimethyls
  • Wound bed 413 may be any type of wound bed, and layer 480 may be formed of other polysiloxane or similar materials, in various other implementations.
  • Perforations 485 may take a range of forms, ranging from small holes, crosses, to slits, and allow fluid exchange with wound bed 413 and skin surface 41 1 through layer 480, to prevent maceration of skin 41 1.
  • Layer 470 may include a layer of material that delivers therapeutics in a slow release manner.
  • therapeutics may include antimicrobials such as antibiotic or silver formulations, local anesthetic for pain reduction, amniotic or placental derived cytokines and growth factors such as BMP, hemostatics and coagulants to stop bleeding, oxygen generating and releasing compounds, exo-or endothermic reagents, etc.
  • Layer 460 may be made of a variety of materials including cotton gauze, polyester or polyamide fibers, or open-cell foams of polyurethane or polyvinyl alcohol. These materials of layer 460 may aid in transfer of exudate 452 from the wound bed 413 to void 437 for removal through lumen 445. Layer 460 may optionally include a super absorbent polymer such as sodium polyacrylate, especially when the intent is to lock the exudate 452 within layer 460.
  • a super absorbent polymer such as sodium polyacrylate
  • target pressure po within an enclosed space such as enclosed space 17, 117, 217, 317, 417, of a wound interface, such as wound interface 15, 115, 215, 315, 415
  • a pressure cycle such as exemplary pressure cycle 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 (see Figures 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 91, 9J, respectively) and the actual pressure p a within the enclosed space of the wound interface may be conformed to the target pressure po so that p a ⁇ po by controlling the input of input fluid, such as input fluid 16, 1 16, 216, 316, 416 into the enclosed space of the wound interface, and by controlling the withdrawal of output fluid, such as output fluid 18, 1 18, 218, 318, 418, out of the enclosed space of the
  • the input fluid may be gas, such as gas 22, 125, or liquid, such as liquid 24, in various implementations.
  • the output fluid may include exudate , such as exudate 19, 152, 252, 352, 452, and any residual gas or liquid from a previous pressure cycle, or any combination thereof.
  • Exemplary pressure cycles 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 are illustrated in Figures 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 91, 9J, respectively, in which the target pressure po within the enclosed space of the wound interface is graphed as a function of time t.
  • pressure cycles 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 are describe in terms of target pressure po
  • the actual pressure po may generally corresponds to target pressure po within the enclosed space, so that pressure cycles 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 may be descriptive of the behavior of the actual pressure p a within the enclosed space.
  • the input fluid in various implementations, has an O2 concentration greater than atmospheric air
  • the wound bed is exposed to fluid with O2 concentration greater than atmospheric air throughout the pressure cycles, in various implementations, which may increase the oxygen supply to the wound bed during therapy with resulting therapeutic benefits.
  • pressure cycles 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 are exemplary only and not limiting, and one or more of these exemplary pressure cycles, various combinations of these exemplary pressure cycles or other pressure cycles may be delivered to the wound bed within the enclosed space as controlled by the control group 130, in various implementations.
  • the control group includes a controller, such as controller 87, 165, and the pressure cycle including period, amplitude, and other characteristics of the pressure cycle may be based upon data, such as data 74, communicated to the controller from a user I/O, such as user I/O 86, 145, by a user. Accordingly, the user may select the pressure cycle(s) to be delivered to the wound bed within the enclosed space, a sequence of the pressure cycles, and characteristics such as amplitude and period of the pressures cycles using the user I/O.
  • a controller such as controller 87, 165
  • the pressure cycle including period, amplitude, and other characteristics of the pressure cycle may be based upon data, such as data 74, communicated to the controller from a user I/O, such as user I/O 86, 145, by a user. Accordingly, the user may select the pressure cycle(s) to be delivered to the wound bed within the enclosed space, a sequence of the pressure cycles, and characteristics such as amplitude and period of the pressures cycles
  • the controller may have pre-programmed pressure cycles in memory, and the controller may include other programs or data in memory to determine the pressure cycle(s) from the data and to implement the pressure cycle(s) using a pump, such as pump 89, 168, valve(s), such as valve 88, 172, 173, 174, and pressure sensor(s), such as pressure sensor 91, 176, 178, as may be included in the control group.
  • a pump such as pump 89, 168, valve(s), such as valve 88, 172, 173, 174, and pressure sensor(s), such as pressure sensor 91, 176, 178, as may be included in the control group.
  • target pressure po p ma x.
  • actual pr6SSUr6 pa within the enclosed space as controlled by the control group may be generally equal to target pressure po throughout pressure cycle 500 ⁇ i. e., p a ⁇ po).
  • target pressure po reduces linearly at rate Si from time to to time ti, and then target pressure po reduces linearly at rate ⁇ 3 ⁇ 4 between time ti and time t2 reaching p mm at time t2.
  • Target pressure po is then maintained at p mm between time t2 and time t3, and then target pressure po increases linearly at rate S3 from p mm to p ma x between time t3 and time t4, as illustrated.
  • Input fluid input into the enclosed space between time t3 and time t4 to increase the pressure p a from p mm to p ma x may have an O2 concentration greater than that of atmospheric air.
  • the wound bed may be exposed to O2 at a concentration greater than that found in atmospheric air during successive pressure cycles 500 when the pressure in each such pressure cycle is increased by fluid having an O2 concentration greater than that of atmospheric air.
  • the wound bed in this example, may, thus, be exposed to O2 concentration greater than that of atmospheric air at pressure pmax between time t3 and time t4.
  • the control group may reduce the actual pressure p a between times to and t2 by withdrawal of output fluid from the enclosed space without any concurrent input of input fluid into the enclosed space. Similarly, the control group may increase the actual pressure p a between times t3 and t4 by input of input fluid into the enclosed space without any concurrent withdrawal of output fluid from the enclosed space. Finally, there is no input of input fluid into the enclosed space and concurrent withdrawal of output fluid from the enclosed space between times t2 and t3, in various implementations of pressure cycle 500. Essentially no fluid is input into the enclosed space and essentially no fluid other than exudate, is withdrawn from the enclosed space between time t2 and time t3, in various implementations of pressure cycle 500.
  • a controller such as controller 480 of wound therapy apparatus 400, may control the withdrawal of output fluid between times to and and the input of input fluid between times t3 and t4.
  • the control group may deliver, for example 12 pressure cycles per hour, 4 pressure cycles per hour, or 3 pressure cycles per hour, according to exemplary pressure cycle 500.
  • pressure cycle 500 may be asymmetrical with time - to being greater than time t4 - t3.
  • Pressure cycle 500 may repeat starting at time t4 (i.e. time t4 is set to time to), or some other pressure cycle, such as pressure cycle 550, 600, 650, 700, 750, 800, 850, 900, 950 may then be initiated starting at time t4.
  • Pressure cycle 500 may remain essentially unchanged over successive cycles, or various parameters of pressure cycle 500, such aS pmax, Pmin, Si, ⁇ 3 ⁇ 4, t3 - t2, t4 - to, may be altered over successive cycles.
  • the control group may determine the various parameters of pressure cycle 500, such as p ma x, pmm, Si, &, - t2, t4 - to, using data communicated from the user I/O, the data being input into the user I/O by the user.
  • Input fluid input into the enclosed space between time tio and time tn in order to increase the actual pressure p a from pmm to pmax may have an O2 concentration greater than that of atmospheric air. Accordingly, the wound bed may be exposed to enhanced oxygen at actual pressure p a greater than pmm for time period tn - tio in exemplary pressure cycle 550. Because generally p am b ⁇ pmax the wound bed may be exposed to enhanced oxygen at actual pressure p a generally greater than or equal to ambient pressure pamb for time period tn - tn, in exemplary pressure cycle 550.
  • the actual pressure p a within the enclosed space may be increased between times tio and tn by input of input fluid into the enclosed space without any concurrent withdrawal of output fluid from the enclosed space.
  • the actual pressure p a within the enclosed space may be decreased between times tn and tn by withdrawal of output fluid from the enclosed space without any concurrent input of input fluid into the enclosed space.
  • the control group may control the input of input fluid between times tio and tn and the withdrawal of output fluid between times tn and tn.
  • there is no input of input fluid into the enclosed space and concurrent withdrawal of output fluid from the enclosed space between times tn and tn in various implementations of pressure cycle 550.
  • the pressure pmax of pressure cycle 550 may be limited, for example in certain embodiments, by the ability of the adhesive, such as adhesive 190, 290, 390, 490 to secure the wound interface to a skin surface, such as skin surface 211 , 311 , 411 , under pressure pmax, which forces the wound interface 15 away from the skin surface.
  • the adhesive such as adhesive 190, 290, 390, 490 to secure the wound interface to a skin surface, such as skin surface 211 , 311 , 411 , under pressure pmax, which forces the wound interface 15 away from the skin surface.
  • Pressure cycle 550 may repeat starting at time tn (i. e., time tn is set to time tio), or some other pressure cycle, such as pressure cycle 500, 600, 650, 700, 750, 800, 850, 900, 950 may then be initiated starting at time tn. Pressure cycle 550 may remain essentially unchanged over successive cycles, or various parameters of pressure cycle 550, such as p m ax, pmm, Sn, S12, tn - tio, tn - tn, tn - tn, may be altered over successive cycles.
  • the control group may deliver several pressure cycles according to pressure cycle 550 and then a pressure cycle according to pressure cycle 500 so that the actual pressure p a varies generally over pressures greater than ambient pressure p am b to deliver enhanced oxygen (hyperbaric) to the wound bed and the actual pressure p a varies over pressures less than ambient pressure p am b that may remove exudate from the wound bed or reseal the adhesive of the wound interface to the skin surface.
  • MAP mean arterial perfusion pressure
  • Pressure cycles 500, 550 may be combined, for example, so that time period tn - tio is about 4 minutes and time period t4 - to is about 2 minutes to deliver hyperbaric therapy to the wound bed for about 2/3 of the pressure cycle period of 6 minutes and to deliver suction therapy for about 1/3 of the pressure cycle period.
  • time period tn - tio is about 4 minutes
  • time period t4 - to is about 2 minutes to deliver hyperbaric therapy to the wound bed for about 2/3 of the pressure cycle period of 6 minutes and to deliver suction therapy for about 1/3 of the pressure cycle period.
  • FIG. 9C Another exemplary pressure cycle 600 is illustrated in Figure 9C, and actual pressure p a may be generally equal to target pressure po throughout pressure cycle 600.
  • target pressure po decreases and increases continuously in a sinusoidal (non-linear) manner, as illustrated in Figure 9C, and, thus actual pressure p a decreases and increases continuously in a sinusoidal manner.
  • target pressure po decreases from time t2o to time t2i reaching p m m at time t2i, target pressure po then increases from p mm to p ma x between time to and time to, and then pressure po decreases from pmax to pmm between time to and time to.
  • target pressure po decreases and increases continuously, as illustrated.
  • Pressure cycle 600 may repeat any number of times. Pressure cycle 600 may remain essentially unchanged over successive cycles, or various parameters of pressure cycle 600, such as p ma x, p m m, or the period to - to, may be altered over successive cycles.
  • the target pressure po may increase in a sinusoidal manner, then maintained at a constant p ma x for some time period, and finally decreasing in a sinusoidal manner.
  • FIG. 9D Another exemplary pressure cycle 650 is illustrated in Figure 9D.
  • target pressure po decreases and then increases continuously as a triangular waveform, as illustrated in Figure 7D, and actual pressure p a may be generally equal to target pressure po throughout pressure cycle 650.
  • pressure cycle 650 is initiated at time to and target pressure po ⁇ pmax.
  • target pressure po decreases linearly from time to to time to reaching p m m at time to, and then target pressure po increases linearly from p m m to p ma x between time to and time to thus completing one pressure cycle.
  • the next pressure cycle starts with target pressure po decreasing linearly from time to to time to reaching p m m at time to.
  • target pressure po decreases and then increases continuously as a triangular waveform, as illustrated.
  • Pressure cycle 650 may repeat any number of times.
  • the input fluid input to increase the actual pressure p a to pmax by the control group may include O2 at a concentration greater than that found in atmospheric air, and such increased O2 may be delivered several times in succession by successive waveforms thereby exposing the wound bed continuously to an oxygen rich environment.
  • FIG. 9E Another exemplary pressure cycle 700 is illustrated in Figure 9E.
  • target pressure po is altered stepwise (pulsatile) between p m m to p ma x and actual pressure pa within the enclosed space is altered in correspondence to target pressure po throughout pressure cycle 700 by the control group.
  • the stepwise increase in target pressure po from pmm to pmax in pressure cycle 700 may blow any residual exudate out of lumen in communication with the enclosed space, such as lumen 245, 345, 347, 445, including fluid pathways in communication with the lumen in order to eliminate blockages caused by solidification therein of exudate including medicaments and other materials that may solidify.
  • the end of a pressure cycle may be initiated by a sudden or abrupt release of pressure pmin towards ambient pressure p a mb by the infusion of a bolus of gas or liquid This may prevent the creation of line-occluding exudate plugs, or if they do form, result in the forced expulsion of an exudate plug by pressure alone or in combination with liquid dissolution.
  • the result may be the elimination or prevention of intra-lumen occlusion and more accurate sensing and delivery of suction therapy.
  • the control group may deliver pulses of input fluid, in conformance to pressure cycle 700 to remove blockages from the lumen including fluid pathways in communication with the lumen or the enclosed space. This may maintain the patency of the suction tubing and enable accurate sensing of target pressure po within the enclosed space.
  • the magnitude of the step may be produced for example, by a high fluid flow rate or by a high-compliance reservoir balloon that is interposed between the fluid source and valve that regulates flow delivered to the enclosed space.
  • the lTlciXimum pr6SSUr6 pmax should be less than pressure that could breach the fluid-tightness of the wound interface. This is dependent on a number of factors including the characteristics of the adhesive that is used to anchor the wound interface to the skin. In general, such pulsed maximum pressure p ma x may be less than about 30-40 mm Hg above ambient pressure pa.
  • FIG. 9F Another exemplary pressure cycle 750 is illustrated in Figure 9F.
  • target pressure po decreases linearly from p ma x to p mm and then target pressure po increases exponentially (non-linearly) from p mm to pmax.
  • Actual pressure p a may be generally equal to target pressure po throughout pressure cycle 750.
  • fluid with oxygen concentration greater than that of atmospheric air may be input between times to and to to increase the actual pressure p a from p mm to pmax, and the actual pressure p a is then maintained constant at pmax for time period to - to to deliver oxygen to the wound bed at pressure p ma x for time period to - to.
  • the cycle 750 repeats starting at time t53 with linear decrease in target pressure po from p ma x to p mm between times to and to followed by exponential increase in target pressure po from p mm to pmax, as illustrated in Figure 9F.
  • FIG. 9G Another exemplary pressure cycle 800 is illustrated in Figure 9G.
  • Actual pressure p a may be generally equal to target pressure po throughout pressure cycle 800, and target pressure po varies linearly from p mm to pmax and from p ma x to p mm , as controlled by the control group. Fluid with oxygen concentration greater than that of atmospheric air may be input by the control group between times teo and to to increase the actual pressure p a to maximum pressure pmax.
  • Target pressure po and, thus, actual pressure p a is maintained constant at p ma x for time period to - t ei, for example to deliver oxygen at pressure pmax to the wound bed, in this exemplary pressure cycle.
  • Target pressure po is maintained constant at p mm for time period to - 1 63, for example to withdraw exudate from the wound bed, in exemplary pressure cycle 800.
  • FIG. 9H Another exemplary pressure cycle 850 is illustrated in Figure 9H.
  • actual pressure p a may be generally equal to target pressure po throughout pressure cycle 850, and target pressure po varies sinusoidally from p ma x to p mm and from p mm to pmax, in exemplary pressure cycle 850.
  • Target pressure po is maintained constant at p mm for time period to - t 71 for example to deliver oxygen at pressure pmax to the wound bed, and target pressure po is maintained constant at pmax for time period to - t 73 for example to withdraw exudate from the wound bed, in exemplary pressure cycle 850.
  • target pressure po decreases and increases continuously linearly in a sawtooth pattern
  • actual pressure p a may be generally equal to target pressure po throughout pressure cycle 900.
  • maximum pressure pmax is greater than ambient pressure p am b in exemplary pressure cycle 900.
  • exemplary pressure cycle 950 illustrated in Figure 9J
  • pressure po is initially at pmm at time to.
  • the control group increases the actual pressure p a in conformance with the target pressure po from p m m to pmax between times to and to by input of input fluid as liquid into the enclosed space.
  • the control group controls the inputting of liquid as the input fluid and withdrawal of the liquid as at least a portion of the output fluid, in this implementation.
  • the liquid which forms at least a portion of the input fluid in this implementation, may provide various therapeutic benefits.
  • the liquid may include, for example, saline solution, proteolytic enzyme solution, biofilm degradation solution, antibiotic lavage, amniotic fluid, platelet- enriched plasma, antibiotic, anesthetic, or other liquid having therapeutic benefits.
  • 50 cc or more of liquid may be input into the enclosed space between times to and to.
  • the input fluid in the form of liquid remains within the enclosed space between times to and to to provide a therapeutic benefit to the wound bed, and the liquid is then generally withdrawn from the enclosed space including any pad, such as pad 250, 450 or dressing, such as dressing 350, within the enclosed space as the actual pressure p a in correspondence to the target pressure po is decreased from p ma x to p m m between times to and to.
  • the therapeutic benefit may include debridement, in various implementations.
  • the decrease in target pressure po between times to and to may mark the beginning of a pressure cycle such as, for example, pressure cycle 500, 550, 600, 650, 700, 750, 850, 900.
  • the decrease in target pressure po from p ma x to p mm between times and to may remove 90% or more of the liquid from the enclosed space including any dressing, pad, or layers, such as layers 460, 470, 480, disposed therein, in certain implementations.
  • Time period - tgi during which the liquid is within the enclosed space at pressure p ma x may range, for example, from about 2 minutes to about 1 hour.
  • Time periods - tgi of less than 1 hour or time periods - t9i of only a few minutes may prevent maceration particularly when the skin surface is coated with adhesive such as cyanoacrylate.
  • No input of input fluid into the enclosed space or withdrawal of output fluid from the enclosed space may occur between times tgi and te, i. e., there is no flow through the enclosed space between times tgi and to, in some implementations.
  • liquid may pass through the enclosed space as input fluid and output fluid simultaneously i. e., the liquid is simultaneously input and withdrawn between times t9i and fc.
  • Pressure cycle 950 may be intermittently interposed between other pressure cycles, such as pressure cycle 500, 550, 600, 650, 700, 750, 800, 850, 900, or pressure cycle 950 may be repeated several times in succession.
  • the wound therapy apparatus may deliver a therapy regimen to the wound bed.
  • the therapy regimen may include a sequence of pressure cycles of the actual pressure p a within the enclosed space in conformance to target pressure po.
  • the pressure cycles may be, for example, any of exemplary pressure cycles 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 and the sequence of pressure cycles may include several consecutive pressure cycles.
  • Example I presents series of pressure cycles as used in exemplary wound therapy regimens delivered to the wound bed by the wound therapy apparatus.
  • Example I demonstrates an exemplary application of these exemplary wound therapy regimens to wound therapy of the wound bed.
  • the pad or the dressing may be omitted from the wound bed during at least portions of the healing process.
  • the absence of the pad or dressing eliminates the need or dressing change and the associated pain and inhibition of the healing processes due to disruption of granulation tissue as well as the attendant costs for medical personnel and various consumables, and may allow for visual inspection of the wound bed and surrounding skin through transparent portions of the wound interface. Because no dressing or pad is used in this implementation, the wound therapy apparatus may be employed until complete healing of the wound bed is achieved.
  • the absence of the dressing or pad, except, perhaps, in the initial exudative phase of wound bed, may permit, for example, lavage of wound bed as well as incubation of stem cells incubation of tissue stroma, proteolytic enzyme soaks, medical maggot debridement or a skin graft.
  • the wound therapy apparatus may be employed until complete healing of the wound bed is achieved.
  • N designates a pressure therapy according to exemplary pressure cycle 500 with gas having O2 concentration greater than atmospheric air input into the enclosed space between times t3 and t4 to increase the actual CSSU C a within the enclosed space to p ma x.
  • humidity may be added to the gas or to other gas(es) in various pressure cycles to prevent drying of the wound bed.
  • O designates a therapy according to exemplary pressure cycle 550 with O2 input into the enclosed space between tw and tn in order to increase the pressure within the enclosed space to p ma x with p ma x being greater than ambient pressure p am b in pressure cycle 550 as used in Example I.
  • Therapy Regimen 3 N/O/N/O (N therapy alternating with O therapy)
  • Therapy Regimen 4 O/O/O/N (three O therapies followed by an N therapy that may reattached the wound interface to the skin surface)
  • each pressure cycle (either O therapy or N therapy) is delivered over 6 minutes, for example, each Therapy Regimen is then delivered over 24 minutes allowing the Therapy Regimen to be delivered 60 times a day.
  • more N therapy may be used, as in exemplary Therapy Regimen 1 and exemplary Therapy Regimen 2, in order to remove exudate, such as exudate 51, 151, 251, 351, 419, and improve circulation.
  • the therapy regimen may switch to N/O/N/O as in exemplary Therapy Regimen 3, and, lastly, O therapy would become the dominant therapy.
  • An occasional N therapy may be interposed with a series of O therapies, as in exemplary Therapy Regimen 4, to reseat the wound interface onto the skin.
  • An exemplary week of prescribed therapy Regimens may be:
  • Therapy Regimen 1 which is all N therapy, is used at the initiation of wound therapy, per Example I, as interstitial edema with large quantities of exudate may be present.
  • the negative target pressures po of Therapy Regimen 1 may draw the exudate from the wound bed and may reduce the edema by withdrawing exudate from the wound bed that causes the edema.
  • the wound therapy changes from Therapy Regimen 1 to Therapy Regimen 2 that interposes O therapy with the N therapy.
  • gas having O2 concentration greater than atmospheric air under target pressure po generally greater than or equal to ambient pressure p am b to deliver O2 to the wound bed in the O therapy may aid in healing while the N therapy may continue to treat the edema by withdrawing exudate from the wound.
  • the wound therapy changes from Therapy Regimen 2 to Therapy Regimen 3 that alternates O therapy with the N therapy as the wound continues to heal.
  • the use of gas having O2 concentration greater than atmospheric air in the O therapy may aid in healing while the continued N therapy may continue to treat the edema by withdrawing exudate from the wound.
  • the wound therapy changes from Therapy Regimen 3 to Therapy Regimen 4, which is predominantly O therapy with one cycle of N therapy every four cycles.
  • the negative pressures of the N therapy may re-adhere the wound interface to the skin thereby prolonging the life of the fluid-tight seal between the wound interface and the skin surface.
  • the ratio of frequency of such negative pressure cycles in relation to the positive pressure cycles may be 1: 1, 1:2 or some other suitable ratio depending on a number of parameters, including the duration and magnitude of the positive pressure cycle.
  • the wound interface may require replacement. Replacement is estimated to be once every 5 to 7 days depending on the location of the wound bed and individual variability.
  • a pressure cycle such as pressure cycle 950 may be included from time to time in any of Therapy Regimen 1, Therapy Regimen 2, Therapy Regimen 3, Therapy Regimen 4 to provide liquid to the wound bed.
  • the liquid may be, for example, saline solution, proteolytic enzyme solution, biofllm degradation solution, antibiotic lavage, amniotic fluid, platelet-enriched plasma, antibiotic, anesthetic, or other liquid having therapeutic benefits.
  • Example I the progression is from initial use of N therapy that treats edema, to a mix ofN therapy with O therapy that both treats edema and promotes healing, and, finally, to predominantly O therapy that promotes healing as the wound bed heals and the edema subsides.
  • Therapy Regimen 4 may be used when the wound is at least halfway healed and there is no longer any significant exudate.
  • Example 1 It is assumed in Example 1 for explanatory purposes that the wound bed heals progressively between Day 1 and Day 7. Of course, healing may require other than a week, and, accordingly, the various Therapy Regimens, such as Therapy Regimens 1, 2, 3, and 4, may be continued for various lengths of time and may be combined as appropriate depending upon the condition of the wound bed.
  • Therapy Regimens 1, 2, 3, and 4 may be linked with one another or with other Therapy Regimens in various ways, in various implementations.
  • the Therapy Regimens such as Therapy Regimens 1, 2, 3, 4, may have other patterns of pressure cycles, for example, O/O/O/O/.
  • the Therapy Regimens in other implementations, may have various numbers and types of cycles, such as pressure cycle 500, 550, 600, 650, 700, 750, 800, 850, 900, 950.
  • the wound therapy apparatus may deliver liquid into the enclosed space of the wound interface as directed by the control group the including controller, and the liquid may have various therapeutic purposes.
  • Operations of the wound therapy apparatus may include selecting the liquid from a liquid source, such as liquid source 84, as the input fluid.
  • Operations of the wound therapy apparatus may include controlling the input of input fluid into the enclosed space of the wound interface or controlling the withdrawal of output fluid out of the enclosed space of the wound interface using the control group in ways appropriate to the therapeutic purpose. For example, liquid as input fluid may be input into the enclosed space and then withdrawn from the enclosed space as output fluid to irrigate the wound bed in order to remove bio-burden or to moisturize the wound bed.
  • liquid as input fluid may be input into the enclosed space and allowed to remain within the enclosed space when the liquid has healing or antiseptic properties.
  • liquid as input fluid may be input into the enclosed space and withdrawn from the enclosed space as output fluid in order to flush out various fluid pathways through which input fluid or output fluid are communicated.
  • Input of liquid or withdrawal of liquid from the enclosed space may be user selected by data communicated to the controller using the user I/O.
  • Input of liquid or gas may be user selected by data communicated to the controller 65 by the user using the user I/O.
  • FIG. 10 Another exemplary method of use of the wound therapy apparatus is illustrated by process flow chart in Figure 10.
  • Operational method 2000 as illustrated in Figure 10 and the associated description is exemplary only.
  • operational method 2000 is entered at step 2001.
  • step 2002 the wound interface of the wound therapy apparatus is secured to the skin surface forming the enclosed space over the wound bed.
  • output fluid is withdrawn from the enclosed space thereby reducing the actual pressure p a within the enclosed space until actual pressure p a generally equals the minimum pressure p mm .
  • Actual pr6SSUr6 a within the enclosed space may then be maintained proximate minimum pressure p mm for time period Ti, as per step 2004.
  • time period Ti may be about 3 to 5 minutes.
  • step 2005 input fluid is input into the enclosed space thereby increasing the actual pressure pa from minimum pressure p m m to maximum pressure p ma x.
  • the input fluid input into the enclosed space at exemplary step 2005 to increase generally the actual pressure p a from minimum pressure p mm to maximum pressure p ma x comprises a gas with an O2 concentration greater than that of atmospheric air.
  • the maximum pressure pmax may be about ambient pressure p am b, the maximum pressure pmax may be greater than ambient pressure p am b, or the maximum pressure pmax may be less than ambient pressure pamb, in various implementations.
  • Actual pressure p a within the enclosed space may then be maintained proximate maximum pressure pmax for time period T2, as per exemplary step 2006.
  • time period T2 may be about 1-3 minutes.
  • output fluid is withdrawn from the enclosed space at step 2007 to reduce the actual pressure p a within the enclosed space until actual p a generally equals the minimum pressure p mm .
  • Actual pressure p a within the enclosed space may then be maintained proximate minimum pressure p mm for time period 73 ⁇ 4, as per step 2008. Because the fluid input into the enclosed space at step 2005 comprises a gas with an O2 concentration greater than that of atmospheric air, the wound bed is exposed to gas with an O2 concentration greater than that of atmospheric air throughout steps 2006, 2007, and 2008, in exemplary operational method 2000.
  • input fluid is input into the enclosed space to increase the actual pressure p a from minimum pressure p mm to maximum pressure pmax.
  • the input fluid at step 2009 comprises liquid, in exemplary operational method 2000.
  • Output fluid is withdrawn from the enclosed space and input fluid is input into the enclosed space sequentially by the wound therapy apparatus in performing steps 2003, 2004, 2005, 2006, 2007, 2008 and 2009, in exemplary operational method 2000, so that either input fluid is being input or output fluid is being withdrawn. Input fluid is not input at the same time output fluid is being withdrawn in performing steps 2003, 2004, 2005, 2006, 2007, 2008 and 2009 of exemplary operational method 2000.
  • liquid is then passed through the enclosed space for time period ⁇ 4.
  • the liquid may be sequentially input into the enclosed space and then withdrawn from the enclosed space or the liquid may be simultaneously input into the enclosed space and withdrawn from the enclosed space, at step 2010.
  • Liquid may be input in pulses to purge blockages within various passages that fluidly communicate with the enclosed space, at step 2010.
  • the liquid may flush out the enclosed space including the wound bed and dressing, remove bioburden or exudate, cleanse the wound bed, hydrate the wound bed.
  • the liquid may be input and withdrawn by instillation (steady flow).
  • the control group may limit the actual pressure p a of the liquid within the enclosed space for example to about ambient pressure p am b in order to prevent dislodgement of the wound interface. For example, when actual pressure p a of the liquid within the enclosed space generally equals ambient pressure p am b as detected by the pressure sensor, the control group may reduce or stop the input of liquid into the enclosed space.
  • Exemplary operational method 2000 then terminates at step 2011.
  • Exemplary method 2000 may be repeated any number of times with various combinations of steps 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010. Note that minimum pressure p mm and maximum pressure / may change between steps 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, and times Ti, T2, T3, T4 as well as minimum pressure p mm and maximum pressure p ma x may be altered during various repetitions of method 2000.
  • Methods of wound therapy may include the step of engaging the wound interface with the skin surface around the wound bed thereby defining the enclosed space over the wound bed.
  • Methods of wound therapy may include the steps of establishing fluid communication between the wound interface, the control group, the liquid source, and the gas source.
  • Methods of wound therapy may include the step of regulating the input of input fluid into the enclosed space in sequence with regulating the withdrawal of output fluid from the enclosed space using the control group operably controlled by a the controller thereby altering the actual pressure p a within the enclosed space in correspondence to target pressure po, the pressure cycle having minimum pressure p mm and maximum pressure p ma x, the input fluid comprising a gas having an O2 concentration greater than atmospheric air.
  • Methods of wound therapy may include the step of removing exudate from the output fluid by flowing the output fluid through a reservoir, such as reservoir 81, 150.
  • Methods of wound therapy may include the step of receiving data using the I/O interface in operable communication with the controller, and communicating the data to the controller thereby altering the pressure cycle or altering the input fluid between liquid and gas.
  • Methods of wound therapy may include the step of delivering a therapy regimen to the wound bed, the therapy regimen comprising a series of pressure cycles of the actual pressure p a within the enclosed space.
  • Methods of wound therapy may include the step of delivering a therapy regimen to the wound bed, the therapy regimen comprising inputting liquid into the enclosed space and may include the step of withdrawing liquid from the enclosed space.
  • Methods of wound therapy may include the programmed delivery of various gasses and liquids to the wound bed as controlled by the controller.
  • Methods of wound therapy may include the step of delivering air to the enclosed space when other gasses and liquids are unavailable.
  • Methods of wound therapy include the step of delivering gas to the enclosed space to produce actual pressure p a within the enclosed space equal to ambient pressure p am b in the event of power failure of the wound therapy device.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne, dans divers aspects, un appareil de traitement de plaie comprenant une interface de plaie, qui définit un espace fermé sur un lit de plaie, qui est étanche lorsqu'elle est fixée à une surface de peau autour du lit de plaie. L'appareil de traitement de plaie peut inclure un groupe de commande qui coopère avec l'interface de plaie pour réguler l'entrée de fluide qui peut comprendre du gaz présentant une concentration en O 2 supérieure à celle de l'air atmosphérique dans l'espace fermé et pour réguler le retrait de fluide de l'espace fermé afin de faire varier une pression réelle p a au sein de l'espace fermé généralement entre une pression minimale p min et une pression maximale p max , la pression minimale p min étant inférieure à la pression ambiante p amb , dans divers aspects. L'entrée de fluide peut être séquentielle avec le retrait du fluide. L'invention concerne également des procédés associés d'utilisation de l'appareil de traitement de plaie.
PCT/US2018/043957 2017-07-29 2018-07-26 Appareil de commande et procédés associés pour l'administration d'un traitement de plaie WO2019027808A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201880049910.5A CN110944608B (zh) 2017-07-29 2018-07-26 伤口治疗递送的控制装置和相关使用方法

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US15/663,710 2017-07-29
US15/663,713 US10729826B2 (en) 2017-07-29 2017-07-29 Wound cover apparatus and related methods of use
US15/663,709 2017-07-29
US15/663,710 US10780201B2 (en) 2017-07-29 2017-07-29 Control apparatus and related methods for wound therapy delivery
US15/663,709 US20190030226A1 (en) 2017-07-29 2017-07-29 Augmented pressure therapy for wounds
US15/663,708 2017-07-29
US15/663,714 2017-07-29
US15/663,714 US11712373B2 (en) 2017-07-29 2017-07-29 Wound therapy apparatus with scar modulation properties and related methods
US15/663,713 2017-07-29
US15/663,708 US11559622B2 (en) 2017-07-29 2017-07-29 Deformation resistant wound therapy apparatus and related methods of use

Publications (1)

Publication Number Publication Date
WO2019027808A1 true WO2019027808A1 (fr) 2019-02-07

Family

ID=63165548

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/US2018/043953 WO2019027806A1 (fr) 2017-07-29 2018-07-26 Appareil de thérapie de plaie résistant à la déformation et procédés d'utilisation associés
PCT/US2018/043955 WO2019027807A1 (fr) 2017-07-29 2018-07-26 Traitement des plaies par pression augmentée
PCT/US2018/043957 WO2019027808A1 (fr) 2017-07-29 2018-07-26 Appareil de commande et procédés associés pour l'administration d'un traitement de plaie
PCT/US2018/043959 WO2019027809A1 (fr) 2017-07-29 2018-07-26 Appareil de recouvrement de plaie et procédés d'utilisation associés
PCT/US2018/043962 WO2019027810A1 (fr) 2017-07-29 2018-07-26 Appareil de traitement de plaie avec propriétés de modulation de cicatrice et procédés associés

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US2018/043953 WO2019027806A1 (fr) 2017-07-29 2018-07-26 Appareil de thérapie de plaie résistant à la déformation et procédés d'utilisation associés
PCT/US2018/043955 WO2019027807A1 (fr) 2017-07-29 2018-07-26 Traitement des plaies par pression augmentée

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2018/043959 WO2019027809A1 (fr) 2017-07-29 2018-07-26 Appareil de recouvrement de plaie et procédés d'utilisation associés
PCT/US2018/043962 WO2019027810A1 (fr) 2017-07-29 2018-07-26 Appareil de traitement de plaie avec propriétés de modulation de cicatrice et procédés associés

Country Status (2)

Country Link
CN (5) CN110944608B (fr)
WO (5) WO2019027806A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729826B2 (en) 2017-07-29 2020-08-04 Edward D. Lin Wound cover apparatus and related methods of use
US10780201B2 (en) 2017-07-29 2020-09-22 Edward D. Lin Control apparatus and related methods for wound therapy delivery
US11559622B2 (en) 2017-07-29 2023-01-24 Edward D. Lin Deformation resistant wound therapy apparatus and related methods of use
US11712373B2 (en) 2017-07-29 2023-08-01 Edward D. Lin Wound therapy apparatus with scar modulation properties and related methods
EP4076220A4 (fr) * 2019-12-20 2023-12-27 Merit Medical Systems, Inc. Dispositif de compression chirurgical gonflable et systèmes et procédés associés
US12036353B2 (en) 2017-07-29 2024-07-16 Edward D. Lin Apparatus and methods for pressure management within a wound chamber

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190351095A1 (en) * 2018-05-21 2019-11-21 Milliken & Company Wound care device having fluid transfer and adhesive properties
US20190351094A1 (en) * 2018-05-21 2019-11-21 Milliken & Company Wound care device having fluid transfer and adhesive properties
GB201917732D0 (en) * 2019-12-04 2020-01-15 Medtrade Products Ltd Absorbent pads for wound dressings
CN112656563B (zh) * 2020-12-28 2022-07-01 吉林大学 一种用于新生儿脐部护理的永磁护脐带
CN113520720B (zh) * 2021-07-15 2022-09-30 上海美宝生命科技有限公司 一种封闭式负压引流敷料系统

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070118096A1 (en) * 2005-11-21 2007-05-24 Smith Joshua D Wound care system
US20080140029A1 (en) * 2006-11-21 2008-06-12 Joshua David Smith Wound care apparatus
WO2009141820A1 (fr) * 2008-05-21 2009-11-26 Morris Topaz Dispositif de cicatrisation de plaie
US20160166781A1 (en) * 2014-08-08 2016-06-16 Neogenix, Llc Oxygen concentrating device, wound care apparatus, and treatment methods
US20170119940A1 (en) * 2004-07-19 2017-05-04 Thermotek, Inc. Wound care and infusion method and system utilizing a therapeutic agent

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2280915A (en) * 1941-04-03 1942-04-28 John H Johnson Device for irrigating and treating wounds
US7198046B1 (en) * 1991-11-14 2007-04-03 Wake Forest University Health Sciences Wound treatment employing reduced pressure
US5622725A (en) * 1992-03-20 1997-04-22 Alcide Corporation Wound disinfection and repair
US5522794A (en) * 1994-06-16 1996-06-04 Hercules Incorporated Method of treating human wounds
US6458109B1 (en) * 1998-08-07 2002-10-01 Hill-Rom Services, Inc. Wound treatment apparatus
US7842306B2 (en) * 2003-08-14 2010-11-30 Milliken & Company Wound care device having fluid transfer properties
GB0325120D0 (en) * 2003-10-28 2003-12-03 Smith & Nephew Apparatus with actives
GB0325129D0 (en) * 2003-10-28 2003-12-03 Smith & Nephew Apparatus in situ
GB0508529D0 (en) * 2005-04-27 2005-06-01 Smith & Nephew Sai with microstress
US7161056B2 (en) * 2005-01-28 2007-01-09 Ossur Hf Wound dressing and method for manufacturing the same
EP2068798A4 (fr) * 2006-08-30 2009-12-16 Southeastern Medical Technolog Méthodes, compositions et appareils pour traiter des blessures au moyen de pressions altérées à partir de pressions atmosphériques
KR20090082914A (ko) * 2006-11-30 2009-07-31 메델라 홀딩 아게 상처를 치료하는 장치
US8377016B2 (en) * 2007-01-10 2013-02-19 Wake Forest University Health Sciences Apparatus and method for wound treatment employing periodic sub-atmospheric pressure
SE531259C2 (sv) * 2007-06-27 2009-02-03 Moelnlycke Health Care Ab Anordning för behandling av sår med reducerat tryck
US8152785B2 (en) * 2008-03-13 2012-04-10 Tyco Healthcare Group Lp Vacuum port for vacuum wound therapy
US8377015B2 (en) * 2009-04-24 2013-02-19 Alcare Co., Ltd. Wound dressing and method for producing it
GB201108229D0 (en) * 2011-05-17 2011-06-29 Smith & Nephew Tissue healing
US8821419B1 (en) * 2011-05-27 2014-09-02 Allen L. Van Beek Flexible interface external micro vacuum chamber tissue expander
JP6208124B2 (ja) * 2011-07-14 2017-10-04 スミス アンド ネフュー ピーエルシーＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ 創傷被覆材および当該創傷被覆材を製造する方法
GB2504873B (en) * 2011-11-01 2015-10-14 Brightwake Ltd Wound dressings, and yarn useful therein
US9393354B2 (en) * 2011-11-01 2016-07-19 J&M Shuler Medical, Inc. Mechanical wound therapy for sub-atmospheric wound care system
EP2626049B1 (fr) * 2012-02-11 2018-07-25 Paul Hartmann AG Dispositif pour la thérapie des plaies
CA2864414C (fr) * 2012-02-13 2021-03-16 Integrated Healing Technologies Appareil de pansement pour plaies
US9035122B2 (en) * 2012-03-05 2015-05-19 Polyremedy, Inc. Wound dressing inhibiting lateral diffusion of absorbed exudate
MX2015001520A (es) * 2012-08-01 2015-08-20 Smith & Nephew Apósito para heridas.
WO2014116783A1 (fr) * 2013-01-24 2014-07-31 The Cleveland Clinic Foundation Appareil et procédé de couverture de plaie
CN103071197A (zh) * 2013-01-29 2013-05-01 绍兴福清卫生用品有限公司 一种可冲洗伤口的负压伤口敷料及其使用方法
JP2016518936A (ja) * 2013-05-10 2016-06-30 スミス アンド ネフュー ピーエルシーＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ 創傷の潅注及び吸引のための流体コネクタ
US9956120B2 (en) * 2013-10-30 2018-05-01 Kci Licensing, Inc. Dressing with sealing and retention interface
EP3666237B1 (fr) * 2014-06-18 2023-11-01 Smith & Nephew plc Pansement
EP2995324A1 (fr) * 2014-09-11 2016-03-16 Mölnlycke Health Care AB Pansement médical
CN204723468U (zh) * 2015-06-23 2015-10-28 秦承雪 一种用于伤口清创、给药给氧的皮肤创伤治疗系统
CN105369476B (zh) * 2015-10-09 2017-12-22 东华大学 一种具有定向导水功能的非织造复合材料及其制备方法
CN106730097A (zh) * 2016-12-23 2017-05-31 中南大学湘雅三医院 一种用于创面清创循环水疗的交替中空负压引流治疗系统

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170119940A1 (en) * 2004-07-19 2017-05-04 Thermotek, Inc. Wound care and infusion method and system utilizing a therapeutic agent
US20070118096A1 (en) * 2005-11-21 2007-05-24 Smith Joshua D Wound care system
US20080140029A1 (en) * 2006-11-21 2008-06-12 Joshua David Smith Wound care apparatus
WO2009141820A1 (fr) * 2008-05-21 2009-11-26 Morris Topaz Dispositif de cicatrisation de plaie
US20160166781A1 (en) * 2014-08-08 2016-06-16 Neogenix, Llc Oxygen concentrating device, wound care apparatus, and treatment methods

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729826B2 (en) 2017-07-29 2020-08-04 Edward D. Lin Wound cover apparatus and related methods of use
US10780201B2 (en) 2017-07-29 2020-09-22 Edward D. Lin Control apparatus and related methods for wound therapy delivery
US11559622B2 (en) 2017-07-29 2023-01-24 Edward D. Lin Deformation resistant wound therapy apparatus and related methods of use
US11712373B2 (en) 2017-07-29 2023-08-01 Edward D. Lin Wound therapy apparatus with scar modulation properties and related methods
US12036353B2 (en) 2017-07-29 2024-07-16 Edward D. Lin Apparatus and methods for pressure management within a wound chamber
EP4076220A4 (fr) * 2019-12-20 2023-12-27 Merit Medical Systems, Inc. Dispositif de compression chirurgical gonflable et systèmes et procédés associés

Also Published As

Publication number Publication date
CN110996866B (zh) 2023-06-02
CN111050711A (zh) 2020-04-21
WO2019027809A1 (fr) 2019-02-07
CN110944608B (zh) 2022-07-26
WO2019027807A1 (fr) 2019-02-07
CN110958866B (zh) 2022-07-19
WO2019027810A1 (fr) 2019-02-07
CN111343949A (zh) 2020-06-26
CN110996866A (zh) 2020-04-10
CN110944608A (zh) 2020-03-31
CN111050711B (zh) 2022-05-27
WO2019027806A1 (fr) 2019-02-07
CN110958866A (zh) 2020-04-03

Similar Documents

Publication Publication Date Title
US10758650B1 (en) Control apparatus for delivery of therapy to wounds and related methods of use
WO2019027808A1 (fr) Appareil de commande et procédés associés pour l'administration d'un traitement de plaie
US11806215B2 (en) Apparatus for wound therapy
US20230256154A1 (en) Sub-atmospheric wound-care system
TWI801403B (zh) 流體交換式治療裝置
US20200000982A1 (en) Sustained variable negative pressure wound treatment and method of controlling same
US8357130B2 (en) Wound care apparatus
US11559622B2 (en) Deformation resistant wound therapy apparatus and related methods of use
US20050186260A1 (en) Medicated gel foam and method of use
WO2007143715A2 (fr) Oxygénothérapie avec ultrasons

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18755600

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18755600

Country of ref document: EP

Kind code of ref document: A1